<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia - Lawrie, TA - 2016 | Cochrane Library</title> <meta content="First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia - Lawrie, TA - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007102.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia - Lawrie, TA - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007102.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007102.pub4" name="dc.identifier" scheme="DOI"/> <meta content="First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia" name="citation_title"/> <meta content="Theresa A Lawrie" name="citation_author"/> <meta content="1st Floor Education Centre, Royal United Hospital" name="citation_author_institution"/> <meta content="Mo'iad Alazzam" name="citation_author"/> <meta content="Beacon Hospital" name="citation_author_institution"/> <meta content="m.alazzam@nhs.net" name="citation_author_email"/> <meta content="John Tidy" name="citation_author"/> <meta content="Sheffield Teaching Hospitals Foundation NHS Trust" name="citation_author_institution"/> <meta content="Barry W Hancock" name="citation_author"/> <meta content="Sheffield University" name="citation_author_institution"/> <meta content="Raymond Osborne" name="citation_author"/> <meta content="Toronto‐Sunnybrook Regional Cancer Centre" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD007102.pub4" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/06/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007102.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007102.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007102.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antineoplastic Agents [*administration &amp; dosage, adverse effects]; Case‐Control Studies; Cohort Studies; Dactinomycin [*administration &amp; dosage, adverse effects]; Drug Administration Schedule; Gestational Trophoblastic Disease [*drug therapy]; Leucovorin [administration &amp; dosage]; Methotrexate [*administration &amp; dosage, adverse effects]; Randomized Controlled Trials as Topic; Risk; Vitamin B Complex [administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007102.pub4&amp;doi=10.1002/14651858.CD007102.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="77cjsSG8";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007102\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007102\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ko","hr","fa","zh_HANS","ja","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007102.pub4",title:"First\\u2010line chemotherapy in low\\u2010risk gestational trophoblastic neoplasia",firstPublishedDate:"Jun 9, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007102.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007102.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007102.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007102.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007102.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007102.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007102.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007102.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007102.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007102.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4788 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007102.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-sec-0099"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-sec-0041"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-sec-0042"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-sec-0093"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/appendices#CD007102-sec-0104"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/table_n/CD007102StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/table_n/CD007102StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/information#CD007102-cr-0002">Theresa A Lawrie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/information#CD007102-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Mo'iad Alazzam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/information#CD007102-cr-0004">John Tidy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/information#CD007102-cr-0005">Barry W Hancock</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007102.pub4/information#CD007102-cr-0006">Raymond Osborne</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/information/en#CD007102-sec-0124">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 June 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007102.pub4">https://doi.org/10.1002/14651858.CD007102.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007102-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007102-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007102-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007102-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007102-abs-0002">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007102-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007102-abs-0001" lang="en"> <section id="CD007102-sec-0001"> <h3 class="title" id="CD007102-sec-0001">Background</h3> <p>This is the second update of a Cochrane review that was first published in 2009, Issue 1. Gestational trophoblastic neoplasia (GTN) is a rare but curable disease arising in the fetal chorion during pregnancy. Most women with low‐risk GTN will be cured by evacuation of the uterus with or without single‐agent chemotherapy. However, chemotherapy regimens vary between treatment centres worldwide and the comparable benefits and risks of these different regimens are unclear. </p> </section> <section id="CD007102-sec-0002"> <h3 class="title" id="CD007102-sec-0002">Objectives</h3> <p>To determine the efficacy and safety of first‐line chemotherapy in the treatment of low‐risk GTN. </p> </section> <section id="CD007102-sec-0003"> <h3 class="title" id="CD007102-sec-0003">Search methods</h3> <p>We electronically searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase in September 2008, February 2012, and January 2016. In addition, we searched online trial registers for protocols and ongoing trials. </p> </section> <section id="CD007102-sec-0004"> <h3 class="title" id="CD007102-sec-0004">Selection criteria</h3> <p>For the original review, we included randomised controlled trials (RCTs), quasi‐RCTs and non‐RCTs that compared first‐line chemotherapy for the treatment of low‐risk GTN. For this updated versions of the review, we included only RCTs. </p> </section> <section id="CD007102-sec-0005"> <h3 class="title" id="CD007102-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed studies for inclusion and extracted data to a pre‐designed data extraction form. Meta‐analysis was performed using the random‐effects model. </p> </section> <section id="CD007102-sec-0006"> <h3 class="title" id="CD007102-sec-0006">Main results</h3> <p>We included seven RCTs (667 women) in this updated review. Most studies were at a low or moderate risk of bias and all compared methotrexate with actinomycin D. Three studies compared weekly intramuscular (IM) methotrexate with bi‐weekly pulsed intravenous (IV) actinomycin D (393 women), one study compared five‐day IM methotrexate with bi‐weekly pulsed IV actinomycin D (75 women), one study compared eight‐day IM methotrexate‐folinic acid (MTX‐FA) with five‐day IV actinomycin D (49 women), and one study compared eight‐day IM MTX‐FA with bi‐weekly pulsed IV actinomycin D. One study contributed no data. </p> <p><i>Moderate‐certainty evidence</i> indicates that actinomycin D is probably more likely to lead to primary cure than methotrexate (risk ratio (RR) 0.65, 95% confidence interval (CI) 0.57 to 0.75; six trials, 577 participants; I<sup>2</sup> = 26%), and first‐line methotrexate treatment is probably more likely to fail than actinomycin D treatment (RR 3.55, 95% CI 1.81 to 6.95; six trials, 577 participants; I<sup>2</sup> = 61%; <i>moderate‐certainty evidence</i>) </p> <p><i>Low‐certainty evidence</i> suggests that there may be little or no difference between methotrexate and actinomycin D treatment with respect to nausea (four studies, 466 women; RR 0.61, 95% CI 0.29 to 1.26) or any of the other individual side‐effects reported, although data for all of these outcomes were insufficient and too inconsistent to be conclusive. <i>Low‐certainty evidence</i> suggests that there may be little or no difference in the risk of severe adverse events (SAEs) between the groups overall (five studies, 515 women; RR 0.35, 95% CI 0.08 to 1.66; I² = 60%); however, the direction of effect favours methotrexate and more evidence is needed. Furthermore, evidence from subgroup analyses suggests that actinomycin D may be associated with a greater risk of SAEs than methotrexate (<i>low‐certainty evidence</i>). We found no evidence on the effect of these treatments on future fertility. </p> </section> <section id="CD007102-sec-0007"> <h3 class="title" id="CD007102-sec-0007">Authors' conclusions</h3> <p>Actinomycin D is probably more likely to achieve a primary cure in women with low‐risk GTN, and less likely to result in treatment failure, than a methotrexate regimen. There may be little or no difference between the pulsed actinomycin D regimen and the methotrexate regimen with regard to side‐effects. However, actinomycin D may be associated with a greater risk of severe adverse events (SAEs) than a methotrexate regimen. Higher‐certainty evidence is still needed on treating low‐risk GTN and the four ongoing trials are likely to make a significant contribution to this field. Given the variety of treatment regimens, findings from these trials could facilitate a network meta‐analysis in the next version of this review to help women and clinicians determine the best treatment options for low‐risk GTN. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007102-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007102-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007102-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007102-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007102-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007102-abs-0013">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007102-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007102-abs-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007102-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007102-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007102-abs-0005" lang="en"> <h3>First‐line treatment with anti‐cancer drugs for low‐risk gestational trophoblastic neoplasia </h3> <p><i>What is the issue?</i><br/> Gestational trophoblastic neoplasia (GTN) is a rare but curable disease whereby a malignant tumour develops in the womb after a normal or molar pregnancy (where tissue develops in the womb instead of a baby). Women with GTN are classified as having low‐ or high‐risk GTN using a specific scoring system. Virtually all women with low‐risk GTN are cured by treatment with chemotherapy (anti‐cancer drugs) after undergoing dilatation and curettage (D&amp;C) of the womb. Methotrexate and actinomycin D are the two most commonly used drugs for first‐line treatment of low‐risk GTN, although methotrexate has been favoured in Europe and North America. Sometimes the first‐line treatment fails to cure the disease or has side‐effects that require it be discontinued, and a secondary treatment has to be used. If methotrexate is the first drug used, actinomycin D is usually the secondary treatment, and vice versa. We undertook this review as it was not clear which drug, if any, was more likely to cure low‐risk disease in the first instance. Furthermore, it was not clear which, if any, caused more side‐effects. </p> <p><i>How was the review conducted?</i><br/> This is an updated version of a review that was first published in 2009. Since undertaking this review, we have searched the literature three times (2008, 2012 and 2016), and have identified seven completed randomised controlled trials (RCTs) and four ongoing trials. The completed trials compared three different treatment methotrexate regimens with two different actinomycin D regimens that differed by drug dose and dosing frequency. We assessed these trials as being at low to moderate risk of bias. We extracted and pooled data where possible, grouping the studies according to the treatments compared in the studies. </p> <p><i>What did we find?</i><br/> Overall, and for each treatment regimen compared, the review evidence shows that actinomycin D is probably more likely to achieve a cure in the first instance than methotrexate, and less likely to fail. Side‐effects were reported to be relatively mild with either treatment and the most commonly experienced side‐effects among women in the studies were nausea, fatigue and anaemia. However, the evidence on side‐effects and serious adverse events is uncertain. Low‐certainty evidence suggests that severe adverse events may be more common with actinomycin D, particularly with the five‐day regimen. </p> <p><i>Conclusions</i><br/> Actinomycin D is probably a more effective treatment than methotrexate but the evidence on side‐effects and severe adverse effects is uncertain and more evidence is needed. More evidence is also needed on the effects of these treatments on future fertility. Four RCTs comparing methotrexate and actinomycin D regimen are currently underway and these will make an important contribution to this field. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007102-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007102-sec-0099"></div> <h3 class="title" id="CD007102-sec-0100">Implications for practice</h3> <section id="CD007102-sec-0100"> <p>Actinomycin D treatment is probably more likely to achieve a primary cure in women with gestational trophoblastic neoplasia (GTN) and less likely to result in treatment failure compared with methotrexate. The evidence on side‐effects and severe adverse events (SAEs) is uncertain; however, actinomycin D may be associated with more SAEs, particularly when given as a five‐day regimen. </p> </section> <h3 class="title" id="CD007102-sec-0101">Implications for research</h3> <section id="CD007102-sec-0101"> <p>The ongoing trials (<a href="./references#CD007102-bbs2-0022" title="ThomasA . Randomised trial of pulsed Actinomycin D versus MTX infusion in low risk gestational trophoblastic neoplasia. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/11/003120 November 19, 2012. ">CTRI/2012/11/003120</a>; <a href="./references#CD007102-bbs2-0023" title="SchinkJC , DiSaia PJ and the Gynecologic Oncology Group. Methotrexate or actinomycin D in treating patients with low‐risk gestational trophoblastic neoplasia. www.clinicaltrials.gov/ct2/show/NCT01535053 14 Feb, 2012. ">GOG 0275</a>; <a href="./references#CD007102-bbs2-0024" title="AbbaslouF . Comparison of pulsed Actinomycin versus 5‐day Methotrexate for the treatment of low‐risk gestational trophoblastic disease in patients. http://www.irct.ir/searchresult.php?id=19567&amp;number=1 Feb 5, 2015. ">IRCT2015012519567N1</a>; <a href="./references#CD007102-bbs2-0025" title="WengD . A multicenter, prospective, randomized trial of methotrexate single‐dose treatment and methotrexate/actinomycin‐D single‐dose treatment in low‐risk gestational trophoblastic neoplasia. https://clinicaltrials.gov/show/NCT01823315 March 21, 2013. ">NCT01823315</a>), projected to include 878 participants altogether should provide the crucial, missing, information on the comparable effects of the more commonly used methotrexate regimens with actinomycin D. In addition, <a href="./references#CD007102-bbs2-0025" title="WengD . A multicenter, prospective, randomized trial of methotrexate single‐dose treatment and methotrexate/actinomycin‐D single‐dose treatment in low‐risk gestational trophoblastic neoplasia. https://clinicaltrials.gov/show/NCT01823315 March 21, 2013. ">NCT01823315</a> may provide useful evidence on a combination regimen. For further information, see <a href="./references#CD007102-sec-0132" title="">Characteristics of ongoing studies</a>. </p> <p>More research is needed to determine whether higher‐scoring, low‐risk lesions (scores of five/six) are best treated with single‐agent therapy, and what the impact of the respective interventions is, if any, on future reproduction. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007102-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007102-sec-0036"></div> <div class="table" id="CD007102-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Actinomycin D compared with methotrexate (MTX) for low‐risk gestational trophoblastic neoplasia (GTN)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: women withe low‐risk GTN</b> </p> <p><b>Settings: outpatient or hospital</b> </p> <p><b>Intervention: actinomycin D (Act D)</b> </p> <p><b>Comparison: MTX</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Illustrative Assumed risk*</b> </p> <p><b>(Act D)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Illustrative Corresponding risk</b> </p> <p><b>(MTX)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary cure (remission)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>824 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>536 per 1000</p> <p>(470 to 618)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.65</b> (0.57 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>577 women (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Act D is probably more likely to achieve a primary cure than MTX.</p> <p>55% of the data came from trials of weekly IM MTX, which may be less effective than the 5‐ or 8‐day MTX regimens. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure of first‐line therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>154 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>547 per 1000 (279 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.55</b> (1.81 to 6.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>577 women (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Act D as a first‐line treatment is probably less likely to fail than MTX.</p> <p>59% of the data came from trials of weekly IM MTX, which may be less effective than the 5‐ or 8‐day MTX regimens. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe adverse events (≥ grade 3)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>142 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> <p>(11 to 235)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.35</b> (0.08 to 1.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>515 women (5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There may be little or no difference between interventions overall. However, the point estimate and subgroup analyses favoured MTX. SAEs occurred in 3 out of 6 studies, but one study did not contribute to the meta‐analysis due to insufficient data. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>462 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>282 per 1000</p> <p>(134 to 582)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.61</b> (0.29 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>466 women (4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is probably little or no difference between MTX and Act D for nausea.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alopecia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Subtotals only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data on alopecia were not pooled due to substantial subgroup differences. However, in general the evidence suggested that there may be little or no difference between MTX and Act D regimens with regard to alopecia, except for the five‐day Act D regimen, which may be more frequently associated with alopecia than the 8‐day MTX regimen. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> <p>IM = intramuscular; SAE = severe adverse effects</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded for clinical or statistical inconsistency </p> <p><sup>2</sup> Downgraded for imprecision </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007102-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007102-sec-0037"></div> <p>This is an updated version of this original review first published in the Cochrane Database of Systematic Reviews, 2009, Issue 1, and re‐published as an update in 2012, Issue 7. </p> <section id="CD007102-sec-0038"> <h3 class="title" id="CD007102-sec-0038">Description of the condition</h3> <p>Gestational trophoblastic disease (GTD) is a rare disease of pregnancy arising in the fetal chorion. It encompasses five main clinicopathologic forms: hydatidiform mole (complete and partial), invasive mole, choriocarcinoma, placental site trophoblastic tumour (PSTT) and epithelioid trophoblastic tumour (ETT). The term gestational trophoblastic neoplasia (GTN) refers only to the invasive and malignant forms of GTD i.e. invasive mole, choriocarcinoma, PSTT and ETT. GTN may develop after a molar or non‐molar pregnancy, irrespective of the site and gestational age, as a consequence of autonomous overgrowth of one of the three cell layers of the trophoblast. </p> <p>The incidence of GTD varies between different regions of the world, with higher rates reported in Indonesia (around 10 per 1000 pregnancies), Mexico (4.6 per 1000) and Japan (two per 1000) and lower rates reported in North America and Europe (less than one per 1000); however, rates differ according to whether studies are population‐based or hospital‐based and may vary between areas within the same country (<a href="./references#CD007102-bbs2-0050" title="LeeC , SmithHO , KimSJ . Epidemiology. In: HancockBW , NewlandsES , BerkowitzRS , ColeLA editor(s). Chapter 3: Gestational Trophoblastic Diseases. 3rd Edition. International Society for the Study of Trophoblastic Diseases, 2009:49‐96. ">Lee 2009</a>). Newer data from North America and Asia suggest that rates of GTD are declining (<a href="./references#CD007102-bbs2-0050" title="LeeC , SmithHO , KimSJ . Epidemiology. In: HancockBW , NewlandsES , BerkowitzRS , ColeLA editor(s). Chapter 3: Gestational Trophoblastic Diseases. 3rd Edition. International Society for the Study of Trophoblastic Diseases, 2009:49‐96. ">Lee 2009</a>). The aetiology of GTD is poorly understood; a previous molar pregnancy and advanced or very young maternal age are associated with an increased risk of GTD; however, other factors including ethnicity, poor nutrition, viral infections and environmental factors may play a role (<a href="./references#CD007102-bbs2-0050" title="LeeC , SmithHO , KimSJ . Epidemiology. In: HancockBW , NewlandsES , BerkowitzRS , ColeLA editor(s). Chapter 3: Gestational Trophoblastic Diseases. 3rd Edition. International Society for the Study of Trophoblastic Diseases, 2009:49‐96. ">Lee 2009</a>). </p> <p>Complete moles (CMs) usually arise as a consequence of duplication of the haploid sperm following fertilisation of an 'empty' ovum, and are therefore diploid and androgenic in origin, with no evidence of fetal tissue. Partial moles (PMs) are typically triploid in origin with two sets of paternal haploid and one set of maternal haploid genes (<a href="./references#CD007102-bbs2-0037" title="FisherR . Genetics. In: BWHancock , MSeckl , RSBerkowitz , LACole editor(s). Gestational Trophoblastic Disease. International Society for the Study of Trophoblastic Diseases. 3rd Edition. ISSTD, 2009. ">Fisher 2009</a>). In most cases, moles resolve spontaneously following one or more uterine evacuations without a need for chemotherapy, however, in approximately 16% of CMs and 0.5% of PMs the disease persists and chemotherapy is required (<a href="./references#CD007102-bbs2-0066" title="SecklMJ . Presentation and management of persistent gestational trophoblastic disease (GTD) and gestational trophoblastic tumours (GTT) in the United Kingdom. In: BWHancock , MSeckl , RSBerkowitz , LACole editor(s). Gestational Trophoblastic Disease, International Society for the Study of Trophoblastic Diseases. 3rd Edition. ISSTD, 2009. ">Seckl 2009</a>). Molar transformation to GTN results in an enlarging uterine mass that may invade locally, metastasise to other sites (most ominously, the liver or brain), and lead to death if left untreated. The most common clinical manifestations of post‐molar GTN are vaginal bleeding, uterine and ovarian enlargement, and raised human chorionic gonadotrophin (hCG) levels (<a href="./references#CD007102-bbs2-0053" title="LurainJR . Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. American Journal of Obstetrics &amp; Gynecology2010;Dec:531‐9. ">Lurain 2010</a>). </p> <p>Moles are considered to have undergone transformation to GTN if four or more hCG values indicate a plateau over a period of at least three weeks, if there is a rise in at least three consecutive hCG values by at least 10% over a two‐week period, if hCG values are raised six months after evacuation, or if there is a histological diagnosis of choriocarcinoma (<a href="./references#CD007102-bbs2-0049" title="KohornEI . The FIGO 2000 staging and risk factor scoring system for gestational trophoblastic neoplasia: a critical analysis. In: BWHancock , MJSeckl , RSBerkowitz , LACole editor(s). Chapter 7: Gestational Trophoblastic Neoplasia. 3rd Edition. www.isstd.org, 2009. ">Kohorn 2009</a>). Urine hCG levels may be helpful in predicting malignant transformation (<a href="./references#CD007102-bbs2-0027" title="AlazzamM , YoungT , ColemanR , HancockB , DrewD , WilsonP , et al. Predicting gestational trophoblastic neoplasia (GTN): is urine hCG the answer?. Gynecologic Oncology2011;122(3):595‐9. ">Alazzam 2011</a>). There is limited evidence that Vitamin A prophylaxis may reduce the risk of malignant transformation (<a href="./references#CD007102-bbs2-0028" title="AndrijonoA , MuhilalM . Prevention of post‐mole malignant trophoblastic disease with vitamin A. Asian Pacific Journal of Cancer Prevention2010;11(2):567‐70. ">Andrijono 2010</a>). </p> <p>Various staging and scoring systems have been developed over the years (<a href="./references#CD007102-bbs2-0029" title="BagshaweKD . Risk and prognostic factors in trophoblastic neoplasia. Cancer1976;38(3):1373‐85. ">Bagshawe 1976</a>; <a href="./references#CD007102-bbs2-0041" title="HammondCB , BorchertLG , TyreyL , CreamanWT , ParkerRT . Treatment of metastatic trophoblastic disease: good and poor prognosis. American Journal of Obstetrics &amp; Gynecology1973;115(4):451‐7. ">Hammond 1973</a>; <a href="./references#CD007102-bbs2-0058" title="NaganHY . The FIGO staging for gestational trophoblastic neoplasia 2000, FIGO Committee Report. International Journal of Gynecology and Obstetrics2002;77:285‐7. ">Nagan 2002</a>; <a href="./references#CD007102-bbs2-0075" title="WHO. Gestatational trophoblastic diseases. WHO Technical report Sens 6921983. ">WHO 1983</a>). The system described by <a href="./references#CD007102-bbs2-0029" title="BagshaweKD . Risk and prognostic factors in trophoblastic neoplasia. Cancer1976;38(3):1373‐85. ">Bagshawe 1976</a> formed the basis of the World Health Organization (WHO) Prognostic scoring System (<a href="./references#CD007102-bbs2-0075" title="WHO. Gestatational trophoblastic diseases. WHO Technical report Sens 6921983. ">WHO 1983</a>) that included age, antecedent pregnancy, interval since antecedent pregnancy, hCG level, ABO blood group, largest tumour site(s) of metastases, site of metastases, and previous chemotherapy. This system was subsequently modified and adapted by the International Federation of Gynecology and Obstetrics (FIGO) <i>(see</i><a href="#CD007102-tbl-0002">Table 1</a>;<a href="#CD007102-tbl-0003">Table 2</a>) (<a href="./references#CD007102-bbs2-0058" title="NaganHY . The FIGO staging for gestational trophoblastic neoplasia 2000, FIGO Committee Report. International Journal of Gynecology and Obstetrics2002;77:285‐7. ">Nagan 2002</a>; <a href="./references#CD007102-bbs2-0036" title="FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary and gestational trophoblastic neoplasia. International Journal of Gynaecology and Obstetrics2009;105:3‐4. ">FIGO 2009</a>). The modified WHO‐FIGO system differs from the WHO system in that the ABO blood group risk factor has been eliminated and the risk factor of liver metastases has been upgraded from two to four. A score of six or less defines 'low‐risk' due to the merging of the old intermediate risk group (previously described by scores of five and six) with the existing low‐risk category (score zero to four). A score of seven or more defines 'high‐risk'. </p> <div class="table" id="CD007102-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">FIGO anatomical staging *</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stage I</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease confined to the uterus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stage II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GTN extends outside of the uterus, but is limited to the genital structures (adnexae, vagina, broad ligament) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stage III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GTN extends to the lungs with or without known genital tract involvement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All other metastatic sites</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*<a href="./references#CD007102-bbs2-0036" title="FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary and gestational trophoblastic neoplasia. International Journal of Gynaecology and Obstetrics2009;105:3‐4. ">FIGO 2009</a><br/> GTN: </p> </div> </div> <div class="table" id="CD007102-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Modified WHO Prognostic Scoring System as adapted by FIGO for GTN</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scores</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age (years)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antecedent pregnancy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mole</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>abortion</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>term</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interval months from index pregnancy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4–6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7–12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pretreatment serum hCG (IU/L)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10<sup>3</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10<sup>3</sup> to 10<sup>4</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10<sup>4</sup> to 10<sup>5</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 10<sup>5</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Largest tumour size (including uterus)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3cm to 4 cm</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 5 cm</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Site of metastases</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>lung</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>spleen, kidney</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>gastrointestinal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>liver, brain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of metastases</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1to 4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 to 8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Previous failed chemotherapy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>single drug</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 2 drugs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><i>To stage and allot a risk factor score, a patient's diagnosis is allocated to a stage as represented by a Roman numeral I, II, III, and IV. This is then separated by a colon from the sum of all the actual risk factor scores expressed in Arabic numerals, i.e., stage II:4, stage IV:9. This stage and score will be allotted for each patient.(</i><a href="./references#CD007102-bbs2-0036" title="FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary and gestational trophoblastic neoplasia. International Journal of Gynaecology and Obstetrics2009;105:3‐4. ">FIGO 2009</a>). <i>A score ≤ 6 indicates low‐risk; &gt; 6 indicates high‐risk.</i> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>hCG = human chorionic gonadotrophin; IU = Internationa Units</p> </div> </div> <p>Low‐risk GTN includes invasive moles and choriocarcinomas that receive a low‐risk score. Once the uterus has been evacuated (preferably by suction curettage to minimise the chance of uterine perforation) and a diagnosis of low‐risk GTN has been made, either histologically or following serial hCG measurements, treatment with single‐agent chemotherapy is usually commenced. FIGO criteria for commencing chemotherapy after evacuation are as follows (<a href="./references#CD007102-bbs2-0055" title="MangiliG , LorussoD , BrownJ , PfistererJ , MassugerL , VaughanM , et al. Trophoblastic disease review for diagnosis and management: A joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup. International Journal of Gynecological Cancer2014;24(9):S109‐S116. ">Mangili 2014</a>): </p> <p> <ul id="CD007102-list-0001"> <li> <p>weekly hCG rising (more than a 10% increase over the previous weekly value) for at least three consecutive measurements for a period of at least three weeks (day 0, 7, and 14); </p> </li> <li> <p>weekly hCG plateauing (less than a 10% change over the previous weekly value) for at least four consecutive measurements for a period of at least three weeks (day 0, 7, 14, and 21); </p> </li> <li> <p>persistence of hCG more than six months after evacuation;</p> </li> <li> <p>histological diagnosis of choriocarcinoma.</p> </li> </ul> </p> <p>Other criteria that may be used include a serum hCG greater than 20,000 IU/L more than four weeks after evacuation, because of the risk of uterine perforation and severe haemorrhage (<a href="./references#CD007102-bbs2-0067" title="SecklMJ , SebireNJ , BerkowitzRS . Gestational trophoblastic disease. Lancet2010;376:717‐29. ">Seckl 2010</a>). </p> </section> <section id="CD007102-sec-0039"> <h3 class="title" id="CD007102-sec-0039">Description of the intervention</h3> <p>There are many effective chemotherapeutic regimens used worldwide for the treatment of low‐risk GTN, mostly involving methotrexate and actinomycin D. The first report of methotrexate therapy for GTN was in 1956 (<a href="./references#CD007102-bbs2-0042" title="HertzR , LiMC , SpencerDB . Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proceedings of the Society of Experimental Biology and Medicine1956;93(2):361‐6. ">Hertz 1956</a>). By 1971, methotrexate had been reported in conjunction with folinic acid as "rescue" from the severe marrow and gestational toxicities seen with high‐dose methotrexate given alone (<a href="./references#CD007102-bbs2-0029" title="BagshaweKD . Risk and prognostic factors in trophoblastic neoplasia. Cancer1976;38(3):1373‐85. ">Bagshawe 1976</a>) and actinomycin D had been reported as a drug of choice for initial therapy (<a href="./references#CD007102-bbs2-0039" title="GoldsteinDP , WinigP , ShirleyRL . Actinomycin D as initial therapy of gestational trophoblastic disease. A reevaluation. Obstetrics &amp; Gynecology1972;39(3):341‐5. ">Goldstein 1972</a>). </p> <p>The most commonly used first‐line regimens for treating low‐risk GTN are as follows.</p> <p> <ul id="CD007102-list-0002"> <li> <p>Methotrexate eight‐day regimen (1 mg/kg intramuscular (IM), days one, three, five and seven) with folinic acid rescue (days two, four six and eight), repeated every 14 to 16 days (<a href="./references#CD007102-bbs2-0030" title="BagshaweKD , DentJ , NewlandsES , BegentRH , RustinGJ . The role of low‐dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). British Journal of Obstetrics and Gynaecology1989;96(7):795‐802. ">Bagshawe 1989</a>; <a href="./references#CD007102-bbs2-0057" title="McNeishIA , StricklandS , HoldenL , RustinGJ , FoskettM , SecklMJ , et al. Low‐risk persistent gestational trophoblastic disease: outcome after initial treatment with low‐dose methotrexate and folinic acid from 1992 to 2000. Journal of Clinical Oncology2002;20(7):1838‐44. ">McNeish 2002</a>); also know as the Charing Cross or Modified Bagshawe regimen. </p> </li> <li> <p>Low‐dose (30 to 50 mg/m²) IM methotrexate, repeated weekly (<a href="./references#CD007102-bbs2-0046" title="HomesleyHD , BlessingJA , RettenmaierM , CapizziRL , MajorFJ , TwiggsLB . Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstetrics and Gynecology1988;72(3 Pt 1):413‐8. ">Homesley 1988</a>; <a href="./references#CD007102-bbs2-0047" title="HomesleyHD , BlessingJA , SchlaerthJ , RettenmaierM , MajorFJ . Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Gynecologic Oncology1990;39(3):305‐8. ">Homesley 1990</a>). </p> </li> <li> <p>Five‐day low‐dose methotrexate (intravenous (IV) or IM); maximum of 25 mg/m² daily for five days, repeated every 14 days (<a href="./references#CD007102-bbs2-0019" title="RobertsJP , LurainJR . Treatment of low‐risk metastatic gestational trophoblastic tumors with single‐agent chemotherapy. American Journal of Obstetrics and Gynecology1996; Vol. 174, issue 6:1917‐23. ">Roberts 1996</a>; <a href="./references#CD007102-bbs2-0070" title="SoperJT , Clarke‐PearsonDL , BerchuckA , RodriguezG , HammondCB . 5‐day methotrexate for women with metastatic gestational trophoblastic disease. Gynecological Oncology1994;54(1):76‐9. ">Soper 1994</a>). </p> </li> <li> <p>Pulsed IV actinomycin D (1.25 mg/m² to a maximum 2 mg single dose), repeated every 14 days (<a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a>; <a href="./references#CD007102-bbs2-0018" title="PetrilliES , MorrowCP . Actinomycin D toxicity in the treatment of trophoblastic disease. Gynecologic Oncology1980;9:18‐22. ">Petrilli 1980</a>; <a href="./references#CD007102-bbs2-0065" title="SchlaerthJB , MorrowCP , NalickRH , GaddisOJr . Single‐dose actinomycin D in the treatment of postmolar trophoblastic disease. Gyncologic Oncology1984;19(1):53‐6. ">Schlaerth 1984</a>; <a href="./references#CD007102-bbs2-0073" title="TwiggsLB . Pulse actinomycin D scheduling in nonmetastatic gestational trophoblastic neoplasia: cost‐effective chemotherapy. Gynecologic Oncology1983;16(2):190‐5. ">Twiggs 1983</a>). </p> </li> <li> <p>Five‐day actinomycin D (0.5 mg IV), repeated every 14 days (<a href="./references#CD007102-bbs2-0015" title="KohornEI . Decision making for chemotherapy administration in patients with low risk gestational trophoblastic neoplasia. International Journal of Gynecological Cancer1996;6:279‐85. ">Kohorn 1996</a>; <a href="./references#CD007102-bbs2-0059" title="OsathanondhR , GoldsteinDP , PastorfideGB . Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer1975;36(3):863‐6. ">Osathanondh 1975</a>). </p> </li> </ul> </p> <p>Other regimens that have been described are included in <a href="#CD007102-tbl-0004">Table 3</a>. Most women with low‐risk GTN will be cured by chemotherapy regardless of the regimen used; however, reported primary remission rates vary and up to 40% per cent of affected women may require additional drug therapy to effect a cure (<a href="./references#CD007102-bbs2-0046" title="HomesleyHD , BlessingJA , RettenmaierM , CapizziRL , MajorFJ , TwiggsLB . Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstetrics and Gynecology1988;72(3 Pt 1):413‐8. ">Homesley 1988</a>; <a href="./references#CD007102-bbs2-0048" title="KhanF , EverardJ , AhmedS , ColemanRE , AitkinM , HancockBW . Low‐risk persistent trophoblastic disease treated with low‐dose methotrexate: efficacy, acute and long term effects. British Journal of Cancer2003;89(12):2197‐201. ">Khan 2003</a>; <a href="./references#CD007102-bbs2-0052" title="LurainJR , ElfstrandEP . Single‐agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. American Journal of Obstetrics and Gynaecology1995;172:574‐9. ">Lurain 1995</a>; <a href="./references#CD007102-bbs2-0057" title="McNeishIA , StricklandS , HoldenL , RustinGJ , FoskettM , SecklMJ , et al. Low‐risk persistent gestational trophoblastic disease: outcome after initial treatment with low‐dose methotrexate and folinic acid from 1992 to 2000. Journal of Clinical Oncology2002;20(7):1838‐44. ">McNeish 2002</a>; <a href="./references#CD007102-bbs2-0070" title="SoperJT , Clarke‐PearsonDL , BerchuckA , RodriguezG , HammondCB . 5‐day methotrexate for women with metastatic gestational trophoblastic disease. Gynecological Oncology1994;54(1):76‐9. ">Soper 1994</a>). In an analysis of 359 women with low‐risk GTN treated between 1979 and 2006 at the Brewer Trophoblastic Center (Chicago), approximately 80% of women were cured with first‐line single‐agent therapy (mainly methotrexate), an additional 10% responded to sequential single‐agent therapy and approximately 10% needed multi‐agent therapy (<a href="./references#CD007102-bbs2-0054" title="LurainJR . Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. American Journal of Obstetrics &amp; Gynecology2011;January:11‐18. ">Lurain 2011</a>). </p> <div class="table" id="CD007102-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Other first‐line chemotherapy regimens described</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravenous (IV) methotrexate (100, 150, or 300 mg/m²) with folinic acid rescue 24 hours later, repeated weekly </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0029" title="BagshaweKD . Risk and prognostic factors in trophoblastic neoplasia. Cancer1976;38(3):1373‐85. ">Bagshawe 1976</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The original Bagshawe regimen.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bolus (100 mg/m² IV or IM) and 12‐hour continuous methotrexate infusion (200 mg/m²) with folinic acid rescue 24 hours later, repeated fortnightly </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0038" title="GarrettAP , GarnerEO , GoldsteinDP , BerkowitzRS . Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low‐risk metastatic gestational trophoblastic tumors. 15 years of experience. Journal of Reproductive Medicine2002;47(5):355‐62. ">Garrett 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Combined 5‐day methotrexate (day 1 to 5) and 5‐day actinomycin D (day 15 to 19), repeated every 28 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0008" title="AbraoRA , deAndradeJM , TiezziDG , MaranaHR , Candido dos ReisFJ , ClagnanWS . Treatment for low‐risk gestational trophoblastic disease: comparison of single‐agent methotrexate, actinomycin D and combination regimens. Gynecologic Oncology2008; Vol. 108, issue 1:149‐53. ">Abrao 2008</a>; <a href="./references#CD007102-bbs2-0068" title="SmithJP . Chemotherapy in gynecologic cancer. Clinical Obstetrics and Gynecology1975;65:113‐6. ">Smith 1975</a>; <a href="./references#CD007102-bbs2-0064" title="RosePG , PiverMS . Alternating methotrexate and actinomycin D in nonmetastatic gestational trophoblastic disease. Journal of Surgical Oncology1989;41(3):148‐52. ">Rose 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Associated with a high incidence of toxicity.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High‐dose methotrexate (600 mg/m²)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0035" title="ElitL , CovensA , OsborneR , GerulathA , MurphyJ , RosenB , et al. High‐dose methotrexate for gestational trophoblastic disease. Gyncologic Oncology1994;54(3):282‐7. ">Elit 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not effect a higher cure than other methotrexate regimens.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Etoposide (oral and parenteral)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0045" title="HitchinsRN , HoldenL , NewlandsES , BegentRH , RustinGJ , BagshaweKD . Single agent etoposide in gestational trophoblastic tumours. Experience at Charing Cross Hospital 1978‐1987. European Journal of Cancer and Clinical Oncology1988;24(6):1041‐6. ">Hitchins 1988</a>; <a href="./references#CD007102-bbs2-0076" title="WongLC , ChooYC , MaHK . Oral etoposide in gestational trophoblastic disease. Cancer Treatment Reports1984;68(5):775‐7. ">Wong 1984</a>; <a href="./references#CD007102-bbs2-0077" title="WongLC , ChooYC , MaHK . Primary oral etoposide therapy in gestational trophoblastic disease. An update. Cancer1986;58(1):14‐7. ">Wong 1986</a>; <a href="./references#CD007102-bbs2-0009" title="BaptistaAM , BelfortP . Comparison of methotrexate, actinomycin D, and etoposide for treating low‐risk gestational trophoblastic neoplasia. International Journal of Gynaecology and Obstetrics2012;119:35‐8. ">Baptista 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported to be highly effective but not widely used for low‐risk GTN due to the high risk of side‐effects, particularly alopecia. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluorouracil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0072" title="SungHC , WuPC , WangYB . Re‐evaluation of 5‐fluorouracil as a single agent for gestational malignant trophoblastic neoplasms. Advances in Experimental Medicine and Biology1984;176:355‐67. ">Sung 1984</a>; <a href="./references#CD007102-bbs2-0069" title="SongHZ , YangXY , XiangY . Forty‐five year's experience of the treatment of choriocarcinoma and invasive mole. International Journal of Gynaecology and Obstetrics1998;60 Suppl 1:S77‐83. ">Song 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Used in China for several decades, mainly because of its low cost, but is not favoured elsewhere. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intra‐lesional methotrexate infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0071" title="SuWH , WangPH , ChangSP . Successful treatment of a persistent mole with myometrial invasion by direct injection of methotrexate. European Journal of Gynaecological Oncology2001;22(4):283‐6. ">Su 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not favoured in Europe or North America.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese preparations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0074" title="WangY , JiuL , GuanY , QiuD . Chemotherapy using 5‐fluorouracil and nitrocaphanum in malignant trophoblastic tumor. Gynecologic Oncology1998;71(3):416‐9. ">Wang 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not favoured in Europe or North America.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>GTN = gestational trophoblastic neoplasia</p> </div> </div> <p>Due to the chemosensitive nature of this disease and its low prevalence, the choice of treatment regimen depends more on geographic location and clinician's experience/preference than high‐quality evidence relating to the relative efficacy and side‐effects of the various regimens. In Europe and North America, there has been a preference for the five‐day or eight‐day methotrexate regimens. On these regimens, women are usually hospitalised for the first cycle due to concerns regarding potential haemorrhage from arteriovenous malformations, and cycles are usually continued for at least three weeks once hCG is normal. </p> <p>Historically, five‐day actinomycin D has been associated with severe alopecia and nausea; therefore, in many centres, it is reserved as salvage therapy in cases of methotrexate resistance or toxicity. However, pulsed actinomycin D every 14 days is reported to be effective, with minimal side‐effects, when used as salvage therapy (<a href="./references#CD007102-bbs2-0031" title="CovensA , FialiciVL , BurgerRA , OsborneR , ChenMD . Phase II trial of pulse actinomycin D as salvage therapy for failed low‐risk gestational trophoblastic neoplasia. Cancer2006;107(6):1280‐6. ">Covens 2006</a>), and as effective as weekly methotrexate when used as first‐line therapy (<a href="./references#CD007102-bbs2-0061" title="PetrilliES , TwiggsLB , BlessingJA , TengNH , CurryS . Single‐dose actinomycin‐D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Oncology Group. Cancer1987;60(9):2173‐6. ">Petrilli 1987</a>; <a href="./references#CD007102-bbs2-0065" title="SchlaerthJB , MorrowCP , NalickRH , GaddisOJr . Single‐dose actinomycin D in the treatment of postmolar trophoblastic disease. Gyncologic Oncology1984;19(1):53‐6. ">Schlaerth 1984</a>; <a href="./references#CD007102-bbs2-0073" title="TwiggsLB . Pulse actinomycin D scheduling in nonmetastatic gestational trophoblastic neoplasia: cost‐effective chemotherapy. Gynecologic Oncology1983;16(2):190‐5. ">Twiggs 1983</a>). In addition, the pulsed actinomycin D regimen has potential advantages over the other regimens in terms of convenience and cost. </p> <p>Drug resistance and toxic side‐effects leading to discontinuation and switching to an alternative regimen may occur with either drug. Predictors of resistance to single‐agent treatment in low‐risk GTN include non‐molar antecedent pregnancy, a histological diagnosis of choriocarcinoma (<a href="./references#CD007102-bbs2-0041" title="HammondCB , BorchertLG , TyreyL , CreamanWT , ParkerRT . Treatment of metastatic trophoblastic disease: good and poor prognosis. American Journal of Obstetrics &amp; Gynecology1973;115(4):451‐7. ">Hammond 1973</a>; <a href="./references#CD007102-bbs2-0052" title="LurainJR , ElfstrandEP . Single‐agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. American Journal of Obstetrics and Gynaecology1995;172:574‐9. ">Lurain 1995</a>), higher pre‐treatment hCG levels (<a href="./references#CD007102-bbs2-0056" title="McgrathS , ShortD , HarveyR , SchmidP , SavagePM , SecklMJ . The management and outcome of women with post‐hydatidiform mole ‘low‐risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IUI‐1̄. British Journal of Cancer2010;102:810‐4. ">McGrath 2010</a>; <a href="./references#CD007102-bbs2-0006" title="Rahimi‐MoghaddamP , EftekharZ , YarandiF . Single‐agent therapy for low risk gestational trophoblastic tumor: a comparison between pulse‐methotrexate versus pulse‐actinomycin [abstract]. International Journal of Gynecological Cancer2004;14 Suppl 1:96. YarandiF , EftekharZ , ShojaeiH , KananiS , SharifiA , HanjaniP . Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics2008; Vol. 103, issue 1:33‐7. ">Yarandi 2008</a>) and higher risk scores (<a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a>). </p> </section> <section id="CD007102-sec-0040"> <h3 class="title" id="CD007102-sec-0040">Why it is important to do this review</h3> <p>We embarked on this systematic review and meta‐analysis because various treatment regimens are used for the first‐line treatment of low‐risk GTN, yet the comparative benefits and risks of these regimens were unclear. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007102-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007102-sec-0041"></div> <p>To assess the efficacy and safety of the various first‐line chemotherapy regimens in the treatment of women with low‐risk GTN. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007102-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007102-sec-0042"></div> <section id="CD007102-sec-0043"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007102-sec-0044"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) comparing first‐line chemotherapy regimens for the treatment of low‐risk gestational trophoblastic neoplasia (GTN). </p> </section> <section id="CD007102-sec-0045"> <h4 class="title">Types of participants</h4> <section id="CD007102-sec-0046"> <h5 class="title">Inclusions</h5> <p>All women with low‐risk GTN (as defined by any of the known risk‐scoring systems), who received primary chemotherapy. Studies that did not provide complete information about the risk‐scoring system, or that did not distinguish a low‐risk group were excluded from the review. </p> </section> <section id="CD007102-sec-0047"> <h5 class="title">Exclusions</h5> <p>Women with high‐risk GTN, placental site trophoblastic tumour (PSTT) or epithelial trophoblastic tumour (ETT). </p> </section> </section> <section id="CD007102-sec-0048"> <h4 class="title">Types of interventions</h4> <p>Any chemotherapeutic agent used in the first‐line treatment of GTN (e.g. methotrexate, actinomycin D, fluorouracil, etoposide) in any dose, duration, frequency and setting. </p> </section> <section id="CD007102-sec-0049"> <h4 class="title">Types of outcome measures</h4> <section id="CD007102-sec-0050"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007102-list-0003"> <li> <p>Primary cure (remission)</p> </li> <li> <p>Failure of first‐line therapy</p> </li> <li> <p>Overall survival (OS)</p> </li> <li> <p>Death due to toxicity</p> </li> <li> <p>Death due to disease</p> </li> </ul> </p> </section> <section id="CD007102-sec-0051"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007102-list-0004"> <li> <p>Mean number of courses or time to first‐line cure</p> </li> <li> <p>Mean number of courses or time to first‐line failure (failure was defined as change in regimen due to drug resistance or toxicity, or surgery for drug resistance) </p> </li> <li> <p>Quality of life (QoL), measured by a validated scale</p> </li> <li> <p>Secondary tumours due to chemotherapy</p> </li> <li> <p>Toxicity due to chemotherapy</p> </li> </ul> </p> <p>Grades of toxicity were extracted according to <a href="./references#CD007102-bbs2-0032" title="Common Terminology Criteria for Adverse Events (CTCAE). National Cancer Institute; available at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html June 14, 2010; Vol. V4.0. ">CTCAE 2010</a>:<br/> (a) haematological (anaemia, neutropenia, abnormal liver function);<br/> (b) gastrointestinal (pain, nausea, vomiting);<br/> (c) genitourinary (vaginal bleeding);<br/> (d) skin (stomatitis, mucositis, alopecia, allergy);<br/> (e) neurological (peripheral and central);<br/> (f) respiratory (pain, shortness of breath, pleural effusion). </p> </section> </section> </section> <section id="CD007102-sec-0052"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007102-sec-0053"> <h4 class="title">Electronic searches</h4> <p>The original search included, Cochrane Central Register of Controlled Trials (CENTRAL, 2008, Issue 3), Ovid MEDLINE (1950 to 2008) and Embase (1980 to 2008) in September 2008. For the previous review update, we re‐ran these database searches to February 2012. </p> <p>For this update we extended the searches to January 2016.</p> <p>CENTRAL (December 2015, Issue 12)<br/> MEDLINE Ovid (2012 to Jan Week 01 2016)<br/> Embase Ovid (2012 to 2016 week 03) </p> <p>The search strategy was broad and we adapted the key words in the strategies in the databases listed in <a href="#CD007102-sec-0054">Searching other resources</a>, as appropriate. We considered papers in all languages. For the original search strategies see <a href="./appendices#CD007102-sec-0105">Appendix 1</a> and for the 2012 update see <a href="./appendices#CD007102-sec-0113">Appendix 2</a> . </p> </section> <section id="CD007102-sec-0054"> <h4 class="title">Searching other resources</h4> <p>In addition to electronic searches, for this update we searched the following for ongoing trials: <a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a> and the International Clinical Trials Registry Platform search portal (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>). We searched reference lists of identified studies for additional articles. </p> </section> </section> <section id="CD007102-sec-0055"> <h3 class="title" id="CD007102-sec-0055">Data collection and analysis</h3> <section id="CD007102-sec-0056"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently selected articles on the basis of title and/or abstract for full‐text scrutiny (Mo'iad Alazzam (MA) and John Tidy (JT) for the original review; MA and Theresa Lawrie (TL) for the updates). We excluded those studies that clearly did not meet the inclusion criteria and obtained the full text of the others. For the original review, MA and JT independently assessed each article to determine whether it met the review eligibility criteria. MA and TL did this for the updates. We resolved difference by discussion between the two review authors or by involving a third review author. </p> </section> <section id="CD007102-sec-0057"> <h4 class="title">Data extraction and management</h4> <p>For the original review, MA and JT independently extracted data using a pre‐designed data extraction form; for the updates, MA and TL performed this using an Excel spread sheet. We included the following information from each study. </p> <p> <ul id="CD007102-list-0005"> <li> <p>Design: description of randomisation method, blinding, number of study centres, study duration and number of study withdrawals. </p> </li> <li> <p>Participants: number, mean age, mean risk score.</p> </li> <li> <p>Intervention; name of chemotherapy agents used, dose, route of administration and schedule. </p> </li> <li> <p>Outcomes: Where possible data was extracted to allow intention‐to‐treat (ITT) analysis. For dichotomous outcomes (e.g. primary cure, adverse events, and number of patients who relapsed or died), we abstracted the number of patients in each treatment arm who experienced the outcome of interest, in order to estimate a risk ratio (RR). For continuous outcomes (e.g. quality of life (QoL) measures and duration of treatment), we extracted the arithmetic mean and standard deviation (SD) of the outcome of interest in each treatment arm. For dichotomous and continuous data, we abstracted the number of patients assessed at the endpoint. If reported, we extracted median and range data too. We noted any scoring systems (e.g. FIGO, WHO, National Cancer Institute (NCI)) used. </p> </li> </ul> <ul id="CD007102-list-0006"> <li> <p>Outcomes: Where possible we extracted data to allow intention‐to‐treat (ITT) analysis. For dichotomous outcomes (e.g. primary cure, adverse events, and number of patients who relapsed or died), we abstracted the number of patients in each treatment arm who experienced the outcome of interest, in order to estimate the RR. For continuous outcomes (e.g. QoL measures and duration of treatment), we extracted the arithmetic mean and SD of the outcome of interest in each treatment arm. For dichotomous and continuous data, we abstracted the number of patients assessed at the endpoint. If reported, we extracted median and range data too. We noted any scoring systems (e.g. FIGO, WHO, NCI) used. </p> </li> </ul> </p> <p>Where the data were insufficient or missing from a trial, we attempted to contact trial investigators for more information. We resolved differences between the review authors by discussion or by referral to a third review author. </p> </section> <section id="CD007102-sec-0058"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias of included studies according to the guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007102-bbs2-0044" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) including the following. </p> <p> <ul id="CD007102-list-0007"> <li> <p>Selection bias (random sequence generation and allocation concealment).</p> </li> <li> <p>Detection bias (blinding of outcome assessment).</p> </li> <li> <p>Attrition bias (incomplete outcome data, loss to follow‐up).</p> </li> <li> <p>Reporting bias (selective reporting of outcomes).</p> </li> <li> <p>Other possible sources of bias.</p> </li> </ul> </p> <p>For more details of 'Risk of bias' assessment, see <a href="./appendices#CD007102-sec-0114">Appendix 3</a>. </p> </section> <section id="CD007102-sec-0059"> <h4 class="title">Measures of treatment effect</h4> <p>We used the following measures of the effect of treatment.</p> <p> <ul id="CD007102-list-0008"> <li> <p>For dichotomous outcomes, we present results as summary RR with 95% confidence intervals (CI). </p> </li> <li> <p>For continuous outcomes, we present results as the mean difference (MD) between treatment arms with the associated SD. </p> </li> </ul> </p> </section> <section id="CD007102-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to extract data on the outcomes only among participants who were assessed at endpoint. We did not impute missing outcome data for the primary outcome. If data were missing or only imputed data were reported, we contacted trial authors to request data on the outcomes only among the participants who were assessed. </p> </section> <section id="CD007102-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between studies by visual inspection of forest plots and by measuring the statistical variation between combined studies using the I² statistic (<a href="./references#CD007102-bbs2-0033" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta‐Analysis in Context (2nd edition). London: BMJ Publication Group, 2001. ">Deeks 2001</a>; <a href="./references#CD007102-bbs2-0043" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). In addition, we applied random‐effects modelling (REM) to all pooled‐effect estimates. When heterogeneity was found, we tried to determine the potential reasons for it by examining individual study characteristics. </p> </section> <section id="CD007102-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>As the largest meta‐analysis included only five studies we did not assess funnel plots.</p> </section> <section id="CD007102-sec-0063"> <h4 class="title">Data synthesis</h4> <p>We grouped studies into those comparing similar chemotherapy regimens. Within these groups we performed meta‐analyses if there were sufficient trials using the <a href="./references#CD007102-bbs2-0063" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a> software. </p> <p> <ul id="CD007102-list-0009"> <li> <p>For dichotomous outcomes, we calculated the RR for each study and pooled these data.</p> </li> <li> <p>For continuous outcomes, we calculated the MD between the treatment arms at the end of follow‐up and pooled these data provided outcomes were measured in a similar way between trials. </p> </li> <li> <p>Random‐effects method was used for all meta‐analyses (<a href="./references#CD007102-bbs2-0034" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">DerSimonian 1986</a>). </p> </li> </ul> </p> <section id="CD007102-sec-0064"> <h5 class="title">Grading of the evidence</h5> <p>We created a 'Summary of findings' table in <a href="./references#CD007102-bbs2-0063" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a> using the GRADE approach (<a href="./references#CD007102-bbs2-0040" title="McMaster University (developed by Evidence Prime, Inc.). GRADEpro [Guideline Development Tool [Software]]. Version Available from gradepro.org. McMaster University (developed by Evidence Prime, Inc.), 2015. ">GRADEpro GDT 2015</a>). For assessments of the overall quality of evidence for each outcome that included pooled data, we downgraded the evidence from 'high quality' by one level for serious (or by two for very serious) study limitations (risk of bias), indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. </p> </section> </section> <section id="CD007102-sec-0065"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In the protocol and for the original review, we did not perform subgroup analyses, but grouped studies into individual comparisons based on the comparative interventions and regimens tested. For the revised review, we compared interventions, subgrouping trials by regimen. Therefore, for trials comparing methotrexate with actinomycin D, we considered the following subgroups where possible. </p> <p> <ol id="CD007102-list-0010"> <li> <p>Weekly IM methotrexate versus bi‐weekly pulsed IV actinomycin D.</p> </li> <li> <p>Five‐day IM methotrexate versus bi‐weekly pulsed IV actinomycin D.</p> </li> <li> <p>Eight‐day IM methotrexate‐folinic acid (MTX‐FA) versus five‐day IV actinomycin D.</p> </li> <li> <p>Five‐day IM methotrexate versus five‐day IV actinomycin D.</p> </li> <li> <p>Eight‐day IM MTX‐FA versus bi‐weekly pulsed IV actinomycin D.</p> </li> <li> <p>Weekly IM methotrexate versus five‐day pulsed actinomycin D.</p> </li> </ol> </p> <p>Although we did not pre‐specify subgroup analyses, we analysed these 'subgroups' in the original review, where possible, as individual comparisons. </p> </section> <section id="CD007102-sec-0066"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analysis to assess the robustness of the meta‐analyses by comparing the results using all trials and then excluding trials of lower methodological quality or those considered to be at a higher risk of bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007102-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007102-sec-0067"></div> <section id="CD007102-sec-0068"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD007102-sec-0130" title="">Characteristics of included studies</a>; <a href="./references#CD007102-sec-0131" title="">Characteristics of excluded studies</a> </p> <section id="CD007102-sec-0069"> <h4 class="title">Results of the search</h4> <p>For the original review, we identified 14 potentially eligible studies and, of these, we included eight studies and excluded six (see <a href="#CD007102-fig-0001">Figure 1</a>). The original version of the review included four non‐randomised studies (NRS). For the first update published in May 2012, which restricted studies to RCTs, only four of the originally included studies met the revised inclusion criteria (<a href="./references#CD007102-bbs2-0001" title="GilaniMM , YarandiF , EftekharZ , HanjaniP . Comparison of pulse methotrexate and pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. Australian and New Zealand Journal of Obstetrics and Gynaecology2005; Vol. 45, issue 2:161‐4. ">Gilani 2005</a>; <a href="./references#CD007102-bbs2-0002" title="LertkhachonsukA , TangtrakulS , IsranguraN , WilailakS . Actinomycin D versus methotrexate‐folinic acid as the treatment of stage 1, low‐risk gestational trophoblastic neoplasia. Conference abstract from the International Society for the Study of Trophoblastic Disease (ISSTD) conference. 2007. LertkhachonsukAA , IsranguraN , WilailakS , TangtrakulS . Actinomycin d versus methotrexate‐folinic acid as the treatment of stage I, low‐risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer2009;19(5):985‐8. ">Lertkhachonsuk 2009</a>; <a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a>; <a href="./references#CD007102-bbs2-0006" title="Rahimi‐MoghaddamP , EftekharZ , YarandiF . Single‐agent therapy for low risk gestational trophoblastic tumor: a comparison between pulse‐methotrexate versus pulse‐actinomycin [abstract]. International Journal of Gynecological Cancer2004;14 Suppl 1:96. YarandiF , EftekharZ , ShojaeiH , KananiS , SharifiA , HanjaniP . Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics2008; Vol. 103, issue 1:33‐7. ">Yarandi 2008</a>). One new study (<a href="./references#CD007102-bbs2-0003" title="MousaviA , CheraghiF , YarandiF , GilaniMM , ShojaeiH . Comparison of pulsed actinomycin D versus 5‐day methotrexate for the treatment of low‐risk gestational trophoblastic disease. International Journal of Gynecology and Obstetrics2012;116(1):39‐42. ">Mousavi 2012</a>) was included and (see <a href="#CD007102-fig-0002">Figure 2</a>), three records relating to the previously included studies (<a href="./references#CD007102-bbs2-0051" title="LertkhachonsukAA , IsranguraN , WilailakS , TangtrakulS . Actinomycin d versus methotrexate‐folinic acid as the treatment of stage I, low‐risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer2009;19(5):985‐8. ">Lertkhachonsuk 2009a</a>; <a href="./references#CD007102-bbs2-0060" title="OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011a</a>; <a href="./references#CD007102-bbs2-0062" title="Rahimi‐MoghaddamP , EftekharZ , YarandiF . Single‐agent therapy for low risk gestational trophoblastic tumor: a comparison between pulse‐methotrexate versus pulse‐actinomycin [abstract]. International Journal of Gynecological Cancer2004;14 Suppl 1:96. ">Rahimi‐Moghaddam 2004</a>) and one ongoing study (<a href="./references#CD007102-bbs2-0023" title="SchinkJC , DiSaia PJ and the Gynecologic Oncology Group. Methotrexate or actinomycin D in treating patients with low‐risk gestational trophoblastic neoplasia. www.clinicaltrials.gov/ct2/show/NCT01535053 14 Feb, 2012. ">GOG 0275</a>) were added. Thus, the previous version of this review included data from five RCTs (with eight references). </p> <div class="figure" id="CD007102-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram of the original 2009 review*The original 2009 review Included four non‐RCTs (Abrao 2008; Kohorn 1996; Smith 1982; Wong 1985) in the qualitative and three (Abrao 2008 not included) in the quantitative meta‐analysis). These non‐RCTs were excluded in the updated review." data-id="CD007102-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram of the original 2009 review</p> <p>*The original 2009 review Included four non‐RCTs (<a href="./references#CD007102-bbs2-0008" title="AbraoRA , deAndradeJM , TiezziDG , MaranaHR , Candido dos ReisFJ , ClagnanWS . Treatment for low‐risk gestational trophoblastic disease: comparison of single‐agent methotrexate, actinomycin D and combination regimens. Gynecologic Oncology2008; Vol. 108, issue 1:149‐53. ">Abrao 2008</a>; <a href="./references#CD007102-bbs2-0015" title="KohornEI . Decision making for chemotherapy administration in patients with low risk gestational trophoblastic neoplasia. International Journal of Gynecological Cancer1996;6:279‐85. ">Kohorn 1996</a>; <a href="./references#CD007102-bbs2-0020" title="SmithEB , WeedJCJr , TyreyL , HammondCB . Treatment of nonmetastatic gestational trophoblastic disease: results of methotrexate alone versus methotrexate‐‐folinic acid. American Journal of Obstetrics and Gynecology1982;144(1):88‐92. ">Smith 1982</a>; <a href="./references#CD007102-bbs2-0021" title="WongLC , ChooYC , MaHK . Methotrexate with citrovorum factor rescue in gestational trophoblastic disease. American Journal of Obstetrics and Gynecology1985; Vol. 152, issue 1:59‐62. ">Wong 1985</a>) in the qualitative and three (<a href="./references#CD007102-bbs2-0008" title="AbraoRA , deAndradeJM , TiezziDG , MaranaHR , Candido dos ReisFJ , ClagnanWS . Treatment for low‐risk gestational trophoblastic disease: comparison of single‐agent methotrexate, actinomycin D and combination regimens. Gynecologic Oncology2008; Vol. 108, issue 1:149‐53. ">Abrao 2008</a> not included) in the quantitative meta‐analysis). These non‐RCTs were excluded in the updated review. </p> </div> </div> </div> <div class="figure" id="CD007102-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram of the updated search conducted from January 2010 to February 2012." data-id="CD007102-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram of the updated search conducted from January 2010 to February 2012.</p> </div> </div> </div> <p>For this 2016 version of the review, the updated search identified 88 records from which we identified six potentially eligible new studies. After full‐text retrieval of these records, two met the inclusion criteria (<a href="#CD007102-fig-0003">Figure 3</a>). One was published as a conference abstract (<a href="./references#CD007102-bbs2-0007" title="YarandiF , AdabiK , HaghiS , HaghiZ . Five days intravascular (IV) methotrexate versus biweekly actinomycin‐D(ACT‐D) in treatment of low‐risk gestational trophoblastic Neoplasia: A randomized clinical trial. International Journal of Gynecological Cancer2015;Conference: 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015 Nice France. Conference Start: 20151024 Conference End: 20151027. Conference Publication::659. ">Yarandi 2015</a>), the other was published in Farsi (<a href="./references#CD007102-bbs2-0005" title="ShobeiriMJ , VejdaniR , MelliMS , MadarekEOS , GarebaghiPM , KhoeiSA , et al. Comparison of methotrexate‐folinic acid versus pulsed actinomycin‐d in treatment of stage i, low risk gestational trophoblastic neoplasia: A randomized clinical trial. [Persian]. Iranian Journal of Obstetrics, Gynecology and Infertility2014;17:1‐11. ">Shobeiri 2014</a>). For the latter, at the time of writing we had been unable to obtain the published manuscript from the investigators. </p> <div class="figure" id="CD007102-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram for the updated search conducted from Feb 2012 to January 2016." data-id="CD007102-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for the updated search conducted from Feb 2012 to January 2016.</p> </div> </div> </div> <p>We identified three additional ongoing trials (<a href="./references#CD007102-bbs2-0022" title="ThomasA . Randomised trial of pulsed Actinomycin D versus MTX infusion in low risk gestational trophoblastic neoplasia. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/11/003120 November 19, 2012. ">CTRI/2012/11/003120</a>; <a href="./references#CD007102-bbs2-0024" title="AbbaslouF . Comparison of pulsed Actinomycin versus 5‐day Methotrexate for the treatment of low‐risk gestational trophoblastic disease in patients. http://www.irct.ir/searchresult.php?id=19567&amp;number=1 Feb 5, 2015. ">IRCT2015012519567N1</a>; <a href="./references#CD007102-bbs2-0025" title="WengD . A multicenter, prospective, randomized trial of methotrexate single‐dose treatment and methotrexate/actinomycin‐D single‐dose treatment in low‐risk gestational trophoblastic neoplasia. https://clinicaltrials.gov/show/NCT01823315 March 21, 2013. ">NCT01823315</a>) from an updated search of clinical trial registries. </p> </section> <section id="CD007102-sec-0070"> <h4 class="title">Included studies</h4> <p>The seven included RCTs enrolled a total of 667 women with low‐risk gestational trophoblastic neoplasia (GTN). Low‐risk GTN was defined by either the earlier WHO/FIGO 2000 scoring system (<a href="./references#CD007102-bbs2-0001" title="GilaniMM , YarandiF , EftekharZ , HanjaniP . Comparison of pulse methotrexate and pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. Australian and New Zealand Journal of Obstetrics and Gynaecology2005; Vol. 45, issue 2:161‐4. ">Gilani 2005</a>; <a href="./references#CD007102-bbs2-0002" title="LertkhachonsukA , TangtrakulS , IsranguraN , WilailakS . Actinomycin D versus methotrexate‐folinic acid as the treatment of stage 1, low‐risk gestational trophoblastic neoplasia. Conference abstract from the International Society for the Study of Trophoblastic Disease (ISSTD) conference. 2007. LertkhachonsukAA , IsranguraN , WilailakS , TangtrakulS . Actinomycin d versus methotrexate‐folinic acid as the treatment of stage I, low‐risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer2009;19(5):985‐8. ">Lertkhachonsuk 2009</a>), or the modified WHO scoring system (<a href="#CD007102-tbl-0003">Table 2</a>; <a href="./references#CD007102-bbs2-0003" title="MousaviA , CheraghiF , YarandiF , GilaniMM , ShojaeiH . Comparison of pulsed actinomycin D versus 5‐day methotrexate for the treatment of low‐risk gestational trophoblastic disease. International Journal of Gynecology and Obstetrics2012;116(1):39‐42. ">Mousavi 2012</a>; <a href="./references#CD007102-bbs2-0005" title="ShobeiriMJ , VejdaniR , MelliMS , MadarekEOS , GarebaghiPM , KhoeiSA , et al. Comparison of methotrexate‐folinic acid versus pulsed actinomycin‐d in treatment of stage i, low risk gestational trophoblastic neoplasia: A randomized clinical trial. [Persian]. Iranian Journal of Obstetrics, Gynecology and Infertility2014;17:1‐11. ">Shobeiri 2014</a>; <a href="./references#CD007102-bbs2-0006" title="Rahimi‐MoghaddamP , EftekharZ , YarandiF . Single‐agent therapy for low risk gestational trophoblastic tumor: a comparison between pulse‐methotrexate versus pulse‐actinomycin [abstract]. International Journal of Gynecological Cancer2004;14 Suppl 1:96. YarandiF , EftekharZ , ShojaeiH , KananiS , SharifiA , HanjaniP . Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics2008; Vol. 103, issue 1:33‐7. ">Yarandi 2008</a>). One study (<a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a>) defined low‐risk GTN as a score of less than or equal to four for women recruited before June 2002, and as less than or equal to six for women recruited from July 2002 and February 2007, following modification of the WHO scoring system. <a href="./references#CD007102-bbs2-0005" title="ShobeiriMJ , VejdaniR , MelliMS , MadarekEOS , GarebaghiPM , KhoeiSA , et al. Comparison of methotrexate‐folinic acid versus pulsed actinomycin‐d in treatment of stage i, low risk gestational trophoblastic neoplasia: A randomized clinical trial. [Persian]. Iranian Journal of Obstetrics, Gynecology and Infertility2014;17:1‐11. ">Shobeiri 2014</a> only included FIGO stage I disease. Another study in the form of a conference abstract only did not state how low‐risk GTN was defined (<a href="./references#CD007102-bbs2-0007" title="YarandiF , AdabiK , HaghiS , HaghiZ . Five days intravascular (IV) methotrexate versus biweekly actinomycin‐D(ACT‐D) in treatment of low‐risk gestational trophoblastic Neoplasia: A randomized clinical trial. International Journal of Gynecological Cancer2015;Conference: 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015 Nice France. Conference Start: 20151024 Conference End: 20151027. Conference Publication::659. ">Yarandi 2015</a>). The included RCTs evaluated the following comparisons (see <a href="#CD007102-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD007102-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Chemotherapy treatment comparisons of included RCTs (solid lines) and ongoing RCTs (dotted lines)" data-id="CD007102-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Chemotherapy treatment comparisons of included RCTs (solid lines) and ongoing RCTs (dotted lines) </p> </div> </div> </div> <section id="CD007102-sec-0071"> <h5 class="title">1. Weekly IM methotrexate versus bi‐weekly pulsed IV actinomycin D</h5> <p>Three trials (<a href="./references#CD007102-bbs2-0001" title="GilaniMM , YarandiF , EftekharZ , HanjaniP . Comparison of pulse methotrexate and pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. Australian and New Zealand Journal of Obstetrics and Gynaecology2005; Vol. 45, issue 2:161‐4. ">Gilani 2005</a>; <a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a>; <a href="./references#CD007102-bbs2-0006" title="Rahimi‐MoghaddamP , EftekharZ , YarandiF . Single‐agent therapy for low risk gestational trophoblastic tumor: a comparison between pulse‐methotrexate versus pulse‐actinomycin [abstract]. International Journal of Gynecological Cancer2004;14 Suppl 1:96. YarandiF , EftekharZ , ShojaeiH , KananiS , SharifiA , HanjaniP . Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics2008; Vol. 103, issue 1:33‐7. ">Yarandi 2008</a>) compared a weekly IM methotrexate regimen with fortnightly pulsed IV actinomycin D. All three trials used the same protocol of treatment (weekly IM methotrexate at 30 mg/m² versus bi‐weekly pulsed IV actinomycin D at 1.25 mg/m²). <a href="./references#CD007102-bbs2-0001" title="GilaniMM , YarandiF , EftekharZ , HanjaniP . Comparison of pulse methotrexate and pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. Australian and New Zealand Journal of Obstetrics and Gynaecology2005; Vol. 45, issue 2:161‐4. ">Gilani 2005</a> (46 women) and <a href="./references#CD007102-bbs2-0006" title="Rahimi‐MoghaddamP , EftekharZ , YarandiF . Single‐agent therapy for low risk gestational trophoblastic tumor: a comparison between pulse‐methotrexate versus pulse‐actinomycin [abstract]. International Journal of Gynecological Cancer2004;14 Suppl 1:96. YarandiF , EftekharZ , ShojaeiH , KananiS , SharifiA , HanjaniP . Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics2008; Vol. 103, issue 1:33‐7. ">Yarandi 2008</a> (131 women) randomised participants in a methotrexate:actinomycin D ratio of 1.5:1 for 'economic reasons'; all participants were evaluated. <a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a> randomised 240 participants in a 1:1 ratio, of whom 214 were analysed. </p> </section> <section id="CD007102-sec-0072"> <h5 class="title">2. Five‐day IM methotrexate versus bi‐weekly pulsed IV actinomycin D</h5> <p><a href="./references#CD007102-bbs2-0003" title="MousaviA , CheraghiF , YarandiF , GilaniMM , ShojaeiH . Comparison of pulsed actinomycin D versus 5‐day methotrexate for the treatment of low‐risk gestational trophoblastic disease. International Journal of Gynecology and Obstetrics2012;116(1):39‐42. ">Mousavi 2012</a> randomised 75 participants in a ratio of 1:2 to receive five‐day methotrexate (0.4 mg/kg daily IM) or actinomycin D (1.25 mg/m² IV bolus) respectively, repeated every 14 days until normal human chorionic gonadotrophin (hCG) levels were obtained. All participants were evaluated. <a href="./references#CD007102-bbs2-0007" title="YarandiF , AdabiK , HaghiS , HaghiZ . Five days intravascular (IV) methotrexate versus biweekly actinomycin‐D(ACT‐D) in treatment of low‐risk gestational trophoblastic Neoplasia: A randomized clinical trial. International Journal of Gynecological Cancer2015;Conference: 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015 Nice France. Conference Start: 20151024 Conference End: 20151027. Conference Publication::659. ">Yarandi 2015</a> also evaluated this comparison in 62 women; however, only a conference abstract for this study was available, which did not describe how many participants were allocated to each treatment group and we were unable to obtain this information from the authors. Therefore, <a href="./references#CD007102-bbs2-0007" title="YarandiF , AdabiK , HaghiS , HaghiZ . Five days intravascular (IV) methotrexate versus biweekly actinomycin‐D(ACT‐D) in treatment of low‐risk gestational trophoblastic Neoplasia: A randomized clinical trial. International Journal of Gynecological Cancer2015;Conference: 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015 Nice France. Conference Start: 20151024 Conference End: 20151027. Conference Publication::659. ">Yarandi 2015</a> contributed no data to this updated review. </p> </section> <section id="CD007102-sec-0073"> <h5 class="title">3. Eight‐day IM methotrexate‐folinic acid versus five‐day IV actinomycin D</h5> <p><a href="./references#CD007102-bbs2-0002" title="LertkhachonsukA , TangtrakulS , IsranguraN , WilailakS . Actinomycin D versus methotrexate‐folinic acid as the treatment of stage 1, low‐risk gestational trophoblastic neoplasia. Conference abstract from the International Society for the Study of Trophoblastic Disease (ISSTD) conference. 2007. LertkhachonsukAA , IsranguraN , WilailakS , TangtrakulS . Actinomycin d versus methotrexate‐folinic acid as the treatment of stage I, low‐risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer2009;19(5):985‐8. ">Lertkhachonsuk 2009</a> randomised 49 participants to receive either five‐day actinomycin D (10 mcg/kg; N = 22) or eight‐day methotrexate‐folinic acid (MTX‐FA) (methotrexate 1 mg/kg, alternate days and folinic acid 0.1 mg/kg alternate days; N = 27). Two participants in each group were not evaluable for the primary outcome. </p> </section> <section id="CD007102-sec-0074"> <h5 class="title">4. Eight‐day IM methotrexate‐folinic acid versus bi‐weekly pulsed IV actinomycin D</h5> <p><a href="./references#CD007102-bbs2-0005" title="ShobeiriMJ , VejdaniR , MelliMS , MadarekEOS , GarebaghiPM , KhoeiSA , et al. Comparison of methotrexate‐folinic acid versus pulsed actinomycin‐d in treatment of stage i, low risk gestational trophoblastic neoplasia: A randomized clinical trial. [Persian]. Iranian Journal of Obstetrics, Gynecology and Infertility2014;17:1‐11. ">Shobeiri 2014</a> randomised 64 participants to receive either eight‐day IM methotrexate‐folinic acid (methotrexate 1 mg/kg, alternate days and folinic acid 0.1 mg/kg alternate days; N = 32) or bi‐weekly pulsed IV actinomycin D (1.25 mg/m² IV; N = 32). </p> <p>Women were followed up in all trials for one year after last treatment. See <a href="./references#CD007102-sec-0130" title="">Characteristics of included studies</a> for further details. </p> </section> <section id="CD007102-sec-0075"> <h5 class="title">Ongoing studies</h5> <p>As at 28 March 2016, there were four ongoing RCTs as follows.</p> <p> <ul id="CD007102-list-0011"> <li> <p><a href="./references#CD007102-bbs2-0023" title="SchinkJC , DiSaia PJ and the Gynecologic Oncology Group. Methotrexate or actinomycin D in treating patients with low‐risk gestational trophoblastic neoplasia. www.clinicaltrials.gov/ct2/show/NCT01535053 14 Feb, 2012. ">GOG 0275</a>: Eight‐day IM methotrexate‐folinic acid or five‐day methotrexate versus bi‐weekly pulsed IV actinomycin D </p> </li> <li> <p><a href="./references#CD007102-bbs2-0022" title="ThomasA . Randomised trial of pulsed Actinomycin D versus MTX infusion in low risk gestational trophoblastic neoplasia. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/11/003120 November 19, 2012. ">CTRI/2012/11/003120</a>: One‐day methotrexate infusion versus bi‐weekly pulsed IV actinomycin D </p> </li> <li> <p><a href="./references#CD007102-bbs2-0024" title="AbbaslouF . Comparison of pulsed Actinomycin versus 5‐day Methotrexate for the treatment of low‐risk gestational trophoblastic disease in patients. http://www.irct.ir/searchresult.php?id=19567&amp;number=1 Feb 5, 2015. ">IRCT2015012519567N1</a>: Five‐day IV methotrexate versus bi‐weekly pulsed IV actinomycin D </p> </li> <li> <p><a href="./references#CD007102-bbs2-0025" title="WengD . A multicenter, prospective, randomized trial of methotrexate single‐dose treatment and methotrexate/actinomycin‐D single‐dose treatment in low‐risk gestational trophoblastic neoplasia. https://clinicaltrials.gov/show/NCT01823315 March 21, 2013. ">NCT01823315</a>: Five‐day IM methotrexate versus IV methotrexate/actinomycin D combined </p> </li> </ul> </p> <p>For more details of the ongoing studies, see <a href="./references#CD007102-sec-0132" title="">Characteristics of ongoing studies</a> and <a href="#CD007102-fig-0004">Figure 4</a>. </p> </section> </section> <section id="CD007102-sec-0076"> <h4 class="title">Excluded studies</h4> <p>For the original review, we excluded six studies (<a href="./references#CD007102-bbs2-0010" title="BerkowitzRS , GoldsteinDP . Methotrexate with citrovorum factor rescue for nonmetastatic gestational trophoblastic neoplasms. Obstetrics and Gynecology1979; Vol. 54, issue 6:725‐8. ">Berkowitz 1979</a>; <a href="./references#CD007102-bbs2-0013" title="GleesonNC , FinanMA , FioricaJV , RobertWS , HoffmanMS , WilsonJ . Nonmetastatic gestational trophoblastic disease. Weekly methotrexate compared with 8‐day methotrexate‐folinic acid. European Journal of Gynaecological Oncology1993; Vol. 14, issue 6:461‐5. ">Gleeson 1993</a>; <a href="./references#CD007102-bbs2-0016" title="MatsuiH , IitsukaY , SekiK , SekiyaS . Comparison of chemotherapies with methotrexate, VP‐16 and actinomycin‐D in low‐risk gestational trophoblastic disease. Remission rates and drug toxicities. Gynecologic and Obstetric Investigation1998; Vol. 46, issue 1:5‐8. ">Matsui 1998</a>; <a href="./references#CD007102-bbs2-0017" title="MatsuiH , SuzukaK , YamazawaK , TanakaN , MitsuhashiA , SekiK , et al. Relapse rate of patients with low‐risk gestational trophoblastic tumour initially treated with single‐agent chemotherapy. Gynecologic Oncology2005; Vol. 96, issue 3:616‐20. ">Matsui 2005</a>; <a href="./references#CD007102-bbs2-0018" title="PetrilliES , MorrowCP . Actinomycin D toxicity in the treatment of trophoblastic disease. Gynecologic Oncology1980;9:18‐22. ">Petrilli 1980</a>; <a href="./references#CD007102-bbs2-0019" title="RobertsJP , LurainJR . Treatment of low‐risk metastatic gestational trophoblastic tumors with single‐agent chemotherapy. American Journal of Obstetrics and Gynecology1996; Vol. 174, issue 6:1917‐23. ">Roberts 1996</a>). All these studies were non‐RCTs, excluded mainly due to a high risk of bias. (<a href="./references#CD007102-sec-0131" title="">Characteristics of excluded studies</a>). </p> <p>For the 2012 updated review, we excluded a further four non‐RCTs, that had been classified as 'included' in the original review (see <a href="#CD007102-sec-0128">Differences between protocol and review</a>), on the basis that they were not RCTs. These non‐randomised studies evaluated the following comparisons. </p> <section id="CD007102-sec-0077"> <h5 class="title">1. Eight‐day methotrexate‐folinic acid versus five‐day methotrexate</h5> <p><a href="./references#CD007102-bbs2-0020" title="SmithEB , WeedJCJr , TyreyL , HammondCB . Treatment of nonmetastatic gestational trophoblastic disease: results of methotrexate alone versus methotrexate‐‐folinic acid. American Journal of Obstetrics and Gynecology1982;144(1):88‐92. ">Smith 1982</a> and <a href="./references#CD007102-bbs2-0021" title="WongLC , ChooYC , MaHK . Methotrexate with citrovorum factor rescue in gestational trophoblastic disease. American Journal of Obstetrics and Gynecology1985; Vol. 152, issue 1:59‐62. ">Wong 1985</a> compared eight‐day MTX‐FA with the five‐day methotrexate regimen. Both studies used the same treatment protocol (methotrexate at 1 mg/kg days one, three, five and seven and folinic acid at 0.1 mg/kg days two, four, six and eight; OR methotrexate 0.4 mg/kg on days one to five). Ninety‐seven participants received MTX‐FA and 72 participants received five‐day methotrexate. Remission rates in <a href="./references#CD007102-bbs2-0021" title="WongLC , ChooYC , MaHK . Methotrexate with citrovorum factor rescue in gestational trophoblastic disease. American Journal of Obstetrics and Gynecology1985; Vol. 152, issue 1:59‐62. ">Wong 1985</a> were 82% versus 79%, respectively; and 82% versus 72% in <a href="./references#CD007102-bbs2-0020" title="SmithEB , WeedJCJr , TyreyL , HammondCB . Treatment of nonmetastatic gestational trophoblastic disease: results of methotrexate alone versus methotrexate‐‐folinic acid. American Journal of Obstetrics and Gynecology1982;144(1):88‐92. ">Smith 1982</a>. </p> </section> <section id="CD007102-sec-0078"> <h5 class="title">2. 'Pulsed' actinomycin D versus five‐day actinomycin D</h5> <p><a href="./references#CD007102-bbs2-0015" title="KohornEI . Decision making for chemotherapy administration in patients with low risk gestational trophoblastic neoplasia. International Journal of Gynecological Cancer1996;6:279‐85. ">Kohorn 1996</a> compared pulsed actinomycin D (1.25 mg/m²; N = 18) with the five‐day actinomycin D (12 mcg/kg; N = 43). Complete response was achieved in 14 out of 18 (77%) and 38/43 (88%) respectively, with a mean number of 4.6 (SD 5.4) versus 2.7 (SD 1.3) courses. Toxicity was reported as 'minimal' in both groups with no further details. </p> </section> <section id="CD007102-sec-0079"> <h5 class="title">3. Five‐day methotrexate versus five‐day actinomycin D versus combination of both</h5> <p><a href="./references#CD007102-bbs2-0008" title="AbraoRA , deAndradeJM , TiezziDG , MaranaHR , Candido dos ReisFJ , ClagnanWS . Treatment for low‐risk gestational trophoblastic disease: comparison of single‐agent methotrexate, actinomycin D and combination regimens. Gynecologic Oncology2008; Vol. 108, issue 1:149‐53. ">Abrao 2008</a> compared three different regimens; five‐day methotrexate (20 mg/m², N = 42), five‐day actinomycin D (12 mcg/kg, N = 42) and the combination of five‐day methotrexate and actinomycin D (methotrexate 20 mg/day and actinomycin D 500 mcg/kg, N = 24). Remission rates were 69%, 61% and 79%, respectively. Adverse effects occurred most frequently in the combined treatment group (62.5%) and least frequently in the actinomycin D group. </p> <p>For the 2016 update, we excluded four NRS, including one comparative study that evaluated three treatments as follows. </p> <p><b>4. Eight‐day methotrexate‐folinic acid versus five‐day actinomycin D versus five‐day etoposide</b> </p> <p>In <a href="./references#CD007102-bbs2-0009" title="BaptistaAM , BelfortP . Comparison of methotrexate, actinomycin D, and etoposide for treating low‐risk gestational trophoblastic neoplasia. International Journal of Gynaecology and Obstetrics2012;119:35‐8. ">Baptista 2012</a>, 60 women with low‐risk gestational trophoblastic neoplasia (LRGTN) (risk score ≤ 6) were assigned to methotrexate (50 mg/day/IM) alternating with folinic acid rescue for eight days (n = 20), five‐day actinomycin D (12 mcg/kg/IV) (n = 20) or etoposide (100 mg/m<sup>2</sup>/IV) (n = 20). Complete responses were 50%, 90% and 100% for methotrexate, actinomycin D and etoposide, respectively. MTX was associated with the least toxicity and alopecia was the most common side‐effect caused by etoposide (occurred in 95% of women). </p> </section> </section> </section> <section id="CD007102-sec-0080"> <h3 class="title">Risk of bias in included studies</h3> <p>The 'Risk of bias' assessment of included studies is graphically represented in <a href="#CD007102-fig-0005">Figure 5</a>. In general, we considered <a href="./references#CD007102-bbs2-0002" title="LertkhachonsukA , TangtrakulS , IsranguraN , WilailakS . Actinomycin D versus methotrexate‐folinic acid as the treatment of stage 1, low‐risk gestational trophoblastic neoplasia. Conference abstract from the International Society for the Study of Trophoblastic Disease (ISSTD) conference. 2007. LertkhachonsukAA , IsranguraN , WilailakS , TangtrakulS . Actinomycin d versus methotrexate‐folinic acid as the treatment of stage I, low‐risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer2009;19(5):985‐8. ">Lertkhachonsuk 2009</a> and <a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a> to be at low risk of bias and the other studies to be at moderate risk of bias due to a lack of clarity about study methods. </p> <div class="figure" id="CD007102-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007102-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD007102-sec-0081"> <h4 class="title">Allocation</h4> <p>The method of randomisation was described in only two trials: <a href="./references#CD007102-bbs2-0002" title="LertkhachonsukA , TangtrakulS , IsranguraN , WilailakS . Actinomycin D versus methotrexate‐folinic acid as the treatment of stage 1, low‐risk gestational trophoblastic neoplasia. Conference abstract from the International Society for the Study of Trophoblastic Disease (ISSTD) conference. 2007. LertkhachonsukAA , IsranguraN , WilailakS , TangtrakulS . Actinomycin d versus methotrexate‐folinic acid as the treatment of stage I, low‐risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer2009;19(5):985‐8. ">Lertkhachonsuk 2009</a> (random number tables) and <a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a> (central randomisation). Only one trial described allocation concealment (<a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a>). </p> </section> <section id="CD007102-sec-0082"> <h4 class="title">Blinding</h4> <p>Neither patients nor physicians were blind to the allocated treatment in <a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a>. Blinding was not described in most of the other studies. The <a href="./references#CD007102-bbs2-0005" title="ShobeiriMJ , VejdaniR , MelliMS , MadarekEOS , GarebaghiPM , KhoeiSA , et al. Comparison of methotrexate‐folinic acid versus pulsed actinomycin‐d in treatment of stage i, low risk gestational trophoblastic neoplasia: A randomized clinical trial. [Persian]. Iranian Journal of Obstetrics, Gynecology and Infertility2014;17:1‐11. ">Shobeiri 2014</a> abstract states that this study was 'single‐blind', however, in the absence of any details we judged the risk of bias for this study (as for the studies) to be unclear for blinding. </p> </section> <section id="CD007102-sec-0083"> <h4 class="title">Incomplete outcome data</h4> <p>Loss to follow‐up was low (less than 20% for all assessable outcomes) in one trial (<a href="./references#CD007102-bbs2-0002" title="LertkhachonsukA , TangtrakulS , IsranguraN , WilailakS . Actinomycin D versus methotrexate‐folinic acid as the treatment of stage 1, low‐risk gestational trophoblastic neoplasia. Conference abstract from the International Society for the Study of Trophoblastic Disease (ISSTD) conference. 2007. LertkhachonsukAA , IsranguraN , WilailakS , TangtrakulS . Actinomycin d versus methotrexate‐folinic acid as the treatment of stage I, low‐risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer2009;19(5):985‐8. ">Lertkhachonsuk 2009</a>) and balanced between treatment arms. Four trials reported complete follow‐up (<a href="./references#CD007102-bbs2-0001" title="GilaniMM , YarandiF , EftekharZ , HanjaniP . Comparison of pulse methotrexate and pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. Australian and New Zealand Journal of Obstetrics and Gynaecology2005; Vol. 45, issue 2:161‐4. ">Gilani 2005</a>; <a href="./references#CD007102-bbs2-0003" title="MousaviA , CheraghiF , YarandiF , GilaniMM , ShojaeiH . Comparison of pulsed actinomycin D versus 5‐day methotrexate for the treatment of low‐risk gestational trophoblastic disease. International Journal of Gynecology and Obstetrics2012;116(1):39‐42. ">Mousavi 2012</a>; <a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a>; <a href="./references#CD007102-bbs2-0006" title="Rahimi‐MoghaddamP , EftekharZ , YarandiF . Single‐agent therapy for low risk gestational trophoblastic tumor: a comparison between pulse‐methotrexate versus pulse‐actinomycin [abstract]. International Journal of Gynecological Cancer2004;14 Suppl 1:96. YarandiF , EftekharZ , ShojaeiH , KananiS , SharifiA , HanjaniP . Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics2008; Vol. 103, issue 1:33‐7. ">Yarandi 2008</a>) and for two trials (<a href="./references#CD007102-bbs2-0005" title="ShobeiriMJ , VejdaniR , MelliMS , MadarekEOS , GarebaghiPM , KhoeiSA , et al. Comparison of methotrexate‐folinic acid versus pulsed actinomycin‐d in treatment of stage i, low risk gestational trophoblastic neoplasia: A randomized clinical trial. [Persian]. Iranian Journal of Obstetrics, Gynecology and Infertility2014;17:1‐11. ">Shobeiri 2014</a>; <a href="./references#CD007102-bbs2-0007" title="YarandiF , AdabiK , HaghiS , HaghiZ . Five days intravascular (IV) methotrexate versus biweekly actinomycin‐D(ACT‐D) in treatment of low‐risk gestational trophoblastic Neoplasia: A randomized clinical trial. International Journal of Gynecological Cancer2015;Conference: 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015 Nice France. Conference Start: 20151024 Conference End: 20151027. Conference Publication::659. ">Yarandi 2015</a>), there was insufficient information on follow‐up to pass judgement. </p> </section> <section id="CD007102-sec-0084"> <h4 class="title">Selective reporting</h4> <p>Protocols were only available for two of the seven trials (<a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a>; <a href="./references#CD007102-bbs2-0005" title="ShobeiriMJ , VejdaniR , MelliMS , MadarekEOS , GarebaghiPM , KhoeiSA , et al. Comparison of methotrexate‐folinic acid versus pulsed actinomycin‐d in treatment of stage i, low risk gestational trophoblastic neoplasia: A randomized clinical trial. [Persian]. Iranian Journal of Obstetrics, Gynecology and Infertility2014;17:1‐11. ">Shobeiri 2014</a>). Five studies reported expected outcomes. Toxicity and adverse effects were insufficiently reported in <a href="./references#CD007102-bbs2-0001" title="GilaniMM , YarandiF , EftekharZ , HanjaniP . Comparison of pulse methotrexate and pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. Australian and New Zealand Journal of Obstetrics and Gynaecology2005; Vol. 45, issue 2:161‐4. ">Gilani 2005</a> but were described as 'minimal'. For <a href="./references#CD007102-bbs2-0005" title="ShobeiriMJ , VejdaniR , MelliMS , MadarekEOS , GarebaghiPM , KhoeiSA , et al. Comparison of methotrexate‐folinic acid versus pulsed actinomycin‐d in treatment of stage i, low risk gestational trophoblastic neoplasia: A randomized clinical trial. [Persian]. Iranian Journal of Obstetrics, Gynecology and Infertility2014;17:1‐11. ">Shobeiri 2014</a> and <a href="./references#CD007102-bbs2-0007" title="YarandiF , AdabiK , HaghiS , HaghiZ . Five days intravascular (IV) methotrexate versus biweekly actinomycin‐D(ACT‐D) in treatment of low‐risk gestational trophoblastic Neoplasia: A randomized clinical trial. International Journal of Gynecological Cancer2015;Conference: 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015 Nice France. Conference Start: 20151024 Conference End: 20151027. Conference Publication::659. ">Yarandi 2015</a> there was insufficient information in the abstract reports to pass judgement on reporting bias. </p> </section> <section id="CD007102-sec-0085"> <h4 class="title">Other potential sources of bias</h4> <p>It is not clear why the data from <a href="./references#CD007102-bbs2-0001" title="GilaniMM , YarandiF , EftekharZ , HanjaniP . Comparison of pulse methotrexate and pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. Australian and New Zealand Journal of Obstetrics and Gynaecology2005; Vol. 45, issue 2:161‐4. ">Gilani 2005</a> and <a href="./references#CD007102-bbs2-0006" title="Rahimi‐MoghaddamP , EftekharZ , YarandiF . Single‐agent therapy for low risk gestational trophoblastic tumor: a comparison between pulse‐methotrexate versus pulse‐actinomycin [abstract]. International Journal of Gynecological Cancer2004;14 Suppl 1:96. YarandiF , EftekharZ , ShojaeiH , KananiS , SharifiA , HanjaniP . Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics2008; Vol. 103, issue 1:33‐7. ">Yarandi 2008</a> were not combined by the investigators, since these trials were conducted in consecutive years by the same investigators, compared the same interventions, and applied the same methodology. For this reason, we performed sensitivity analyses, by excluding the <a href="./references#CD007102-bbs2-0001" title="GilaniMM , YarandiF , EftekharZ , HanjaniP . Comparison of pulse methotrexate and pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. Australian and New Zealand Journal of Obstetrics and Gynaecology2005; Vol. 45, issue 2:161‐4. ">Gilani 2005</a> data in case these data were duplicated in <a href="./references#CD007102-bbs2-0006" title="Rahimi‐MoghaddamP , EftekharZ , YarandiF . Single‐agent therapy for low risk gestational trophoblastic tumor: a comparison between pulse‐methotrexate versus pulse‐actinomycin [abstract]. International Journal of Gynecological Cancer2004;14 Suppl 1:96. YarandiF , EftekharZ , ShojaeiH , KananiS , SharifiA , HanjaniP . Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics2008; Vol. 103, issue 1:33‐7. ">Yarandi 2008</a>. For <a href="./references#CD007102-bbs2-0005" title="ShobeiriMJ , VejdaniR , MelliMS , MadarekEOS , GarebaghiPM , KhoeiSA , et al. Comparison of methotrexate‐folinic acid versus pulsed actinomycin‐d in treatment of stage i, low risk gestational trophoblastic neoplasia: A randomized clinical trial. [Persian]. Iranian Journal of Obstetrics, Gynecology and Infertility2014;17:1‐11. ">Shobeiri 2014</a>, and <a href="./references#CD007102-bbs2-0007" title="YarandiF , AdabiK , HaghiS , HaghiZ . Five days intravascular (IV) methotrexate versus biweekly actinomycin‐D(ACT‐D) in treatment of low‐risk gestational trophoblastic Neoplasia: A randomized clinical trial. International Journal of Gynecological Cancer2015;Conference: 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015 Nice France. Conference Start: 20151024 Conference End: 20151027. Conference Publication::659. ">Yarandi 2015</a> there was insufficient information to pass judgement on other potential sources of bias. </p> </section> </section> <section id="CD007102-sec-0086"> <h3 class="title" id="CD007102-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD007102-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <p>One trial (<a href="./references#CD007102-bbs2-0007" title="YarandiF , AdabiK , HaghiS , HaghiZ . Five days intravascular (IV) methotrexate versus biweekly actinomycin‐D(ACT‐D) in treatment of low‐risk gestational trophoblastic Neoplasia: A randomized clinical trial. International Journal of Gynecological Cancer2015;Conference: 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015 Nice France. Conference Start: 20151024 Conference End: 20151027. Conference Publication::659. ">Yarandi 2015</a>) contributed no data to this update. Therefore, six RCTs evaluated 581 women who were randomly allocated to receive methotrexate or actinomycin D for low‐risk GTN. </p> <section id="CD007102-sec-0087"> <h4 class="title">1. Methotrexate versus Actinomycin D</h4> <section id="CD007102-sec-0088"> <h5 class="title">1.1 Primary cure (remission)</h5> <p>Irrespective of the type of regimen used, actinomycin D is probably more likely to lead to a primary cure than methotrexate in women with low‐risk GTN (risk ratio (RR) 0.65, 95% confidence interval (CI) 0.57 to 0.75; six trials, 577 participants; I<sup>2</sup> = 26%; <i>moderate‐certainty evidence,</i> downgraded due clinical inconsistency; <a href="./references#CD007102-fig-0006" title="">Analysis 1.1</a>). </p> <p>Due to concerns related to <a href="#CD007102-sec-0085">Other potential sources of bias</a>, we performed sensitivity analysis, excluding <a href="./references#CD007102-bbs2-0001" title="GilaniMM , YarandiF , EftekharZ , HanjaniP . Comparison of pulse methotrexate and pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. Australian and New Zealand Journal of Obstetrics and Gynaecology2005; Vol. 45, issue 2:161‐4. ">Gilani 2005</a>, and obtained similar results (RR 0.66, 95% CI 0.57 to 0.77). </p> <p>Tests for subgroup differences indicated no heterogeneity between treatment subgroups for this outcome (I² = 0%). </p> </section> <section id="CD007102-sec-0089"> <h5 class="title">1.2 Failure of first‐line therapy</h5> <p>First‐line chemotherapy is probably more likely to fail with methotrexate regimen than with actinomycin D regimen (RR 3.55, 95% CI 1.81 to 6.95; six trials, 577 participants; I<sup>2</sup> = 61%; <a href="./references#CD007102-fig-0007" title="">Analysis 1.2</a>; <i>moderate‐certainty evidence,</i> downgraded due inconsistency). As in Analysis 1.1, a sensitivity analysis, excluding <a href="./references#CD007102-bbs2-0001" title="GilaniMM , YarandiF , EftekharZ , HanjaniP . Comparison of pulse methotrexate and pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. Australian and New Zealand Journal of Obstetrics and Gynaecology2005; Vol. 45, issue 2:161‐4. ">Gilani 2005</a>, produced similar results. </p> <p>Tests for subgroup differences indicated no heterogeneity between treatment subgroups for this outcome (I² = 0%). The <a href="./references#CD007102-bbs2-0002" title="LertkhachonsukA , TangtrakulS , IsranguraN , WilailakS . Actinomycin D versus methotrexate‐folinic acid as the treatment of stage 1, low‐risk gestational trophoblastic neoplasia. Conference abstract from the International Society for the Study of Trophoblastic Disease (ISSTD) conference. 2007. LertkhachonsukAA , IsranguraN , WilailakS , TangtrakulS . Actinomycin d versus methotrexate‐folinic acid as the treatment of stage I, low‐risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer2009;19(5):985‐8. ">Lertkhachonsuk 2009</a> data included six women in the methotrexate‐folinic acid (MTX‐FA) group who were changed to second‐line therapy due to chemotoxicity. When we excluded these women, the results were similar. </p> </section> <section id="CD007102-sec-0090"> <h5 class="title">1.3 Chemotherapy cycles to primary cure</h5> <p>The combined data for this outcome was substantially heterogeneous and findings differed according to treatment subgroups (I² = 75.6%, P value = 0.04), therefore, we present these results as subtotals only. </p> <p>For the subgroup of trials comparing weekly IM methotrexate versus bi‐weekly pulsed IV actinomycin D, fewer cycles of actinomycin D were needed to effect a primary cure (two trials, 346 participants; mean difference (MD) 3.04, 95% CI 0.93 to 5.14; <a href="./references#CD007102-fig-0008" title="">Analysis 1.3</a>). There was substantial heterogeneity between the two trials included in this subgroup (I² = 92%). </p> <p>The other subgroups included only one trial for this outcome (<a href="./references#CD007102-fig-0008" title="">Analysis 1.3</a>). </p> <p><a href="./references#CD007102-bbs2-0003" title="MousaviA , CheraghiF , YarandiF , GilaniMM , ShojaeiH . Comparison of pulsed actinomycin D versus 5‐day methotrexate for the treatment of low‐risk gestational trophoblastic disease. International Journal of Gynecology and Obstetrics2012;116(1):39‐42. ">Mousavi 2012</a> reported that significantly fewer cycles were necessary in the five‐day IM methotrexate group than in the pulsed IV actinomycin D group, however, this trial included secondary treatment cycles in these data. </p> <p>In <a href="./references#CD007102-bbs2-0002" title="LertkhachonsukA , TangtrakulS , IsranguraN , WilailakS . Actinomycin D versus methotrexate‐folinic acid as the treatment of stage 1, low‐risk gestational trophoblastic neoplasia. Conference abstract from the International Society for the Study of Trophoblastic Disease (ISSTD) conference. 2007. LertkhachonsukAA , IsranguraN , WilailakS , TangtrakulS . Actinomycin d versus methotrexate‐folinic acid as the treatment of stage I, low‐risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer2009;19(5):985‐8. ">Lertkhachonsuk 2009</a>, there was no clear difference between the eight‐day MTX‐FA group and the five‐day IV actinomycin D group with regard to the number of cycles. </p> </section> <section id="CD007102-sec-0091"> <h5 class="title">1.4 to 1.14 Adverse effects</h5> <p>The most commonly occurring side‐effects in both groups were nausea, fatigue (constitutional) and anaemia. Findings indicate that there may be little or no difference between a methotrexate and actinomycin D regimen, overall or for subgroup analyses, in the following side‐effects and adverse events. </p> <p> <ul id="CD007102-list-0012"> <li> <p>Nausea (four trials, 466 participants; RR 0.61, 95% CI 0.29 to 1.26; <a href="./references#CD007102-fig-0009" title="">Analysis 1.4</a>; I² = 80%). </p> </li> <li> <p>Vomiting (three trials, 420 participants; RR 0.75, 95% CI 0.32 to 1.73; <a href="./references#CD007102-fig-0010" title="">Analysis 1.5</a>; I² = 64%). </p> </li> <li> <p>Diarrhoea (three trials, 419 participants; RR 1.43, 95% CI 0.85 to 2.41; <a href="./references#CD007102-fig-0011" title="">Analysis 1.6</a>; I² = 0%). </p> </li> <li> <p>Fatigue (constitutional) (three trials, 420 participants; RR 1.00, 95% CI 0.84 to 1.19; <a href="./references#CD007102-fig-0012" title="">Analysis 1.7</a>; I² = 0%). </p> </li> <li> <p>Neutropenia (four trials, 469 participants; RR 0.83, 95% CI 0.48 to 1.45; <a href="./references#CD007102-fig-0016" title="">Analysis 1.11</a> I² = 4%). </p> </li> <li> <p>Thrombocytopenia (three trials, 338 participants; RR 0.76, 95% CI 0.16 to 3.55; <a href="./references#CD007102-fig-0017" title="">Analysis 1.12</a>; I² = 65%). </p> </li> <li> <p>Anaemia (one trial, 214 participants; <a href="./references#CD007102-fig-0018" title="">Analysis 1.13</a>). </p> </li> <li> <p>Hepatotoxicity (two trials, 263 participants; RR 2.57, 95% CI 0.39 to 16.88; <a href="./references#CD007102-fig-0019" title="">Analysis 1.14</a>). </p> </li> <li> <p>Haemoptysis (two trials, 206 participants; RR 0.99, 95% CI 0.30 to 3.31; <a href="./references#CD007102-fig-0020" title="">Analysis 1.15</a>). </p> </li> </ul> </p> <p>This evidence is mostly of low certainty.</p> <section id="CD007102-sec-0092"> <h6 class="title">Other adverse effects</h6> <p>Three studies reported alopecia. There was no significant difference in the rate of women experiencing alopecia in the two studies that compared methotrexate (weekly or five‐day IM) with pulsed IV actinomycin D (206 participants; RR 0.91, 95% CI 0.43 to 1.90; I² = 0%; <a href="./references#CD007102-fig-0013" title="">Analysis 1.8</a>). However, in the one study that compared eight‐day IM MTX‐FA with five‐day IV actinomycin D (<a href="./references#CD007102-bbs2-0002" title="LertkhachonsukA , TangtrakulS , IsranguraN , WilailakS . Actinomycin D versus methotrexate‐folinic acid as the treatment of stage 1, low‐risk gestational trophoblastic neoplasia. Conference abstract from the International Society for the Study of Trophoblastic Disease (ISSTD) conference. 2007. LertkhachonsukAA , IsranguraN , WilailakS , TangtrakulS . Actinomycin d versus methotrexate‐folinic acid as the treatment of stage I, low‐risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer2009;19(5):985‐8. ">Lertkhachonsuk 2009</a>), significantly more women in the actinomycin D group experienced alopecia (49 participants; RR 0.03, 95% CI 0.00 to 0.53; <a href="./references#CD007102-fig-0013" title="">Analysis 1.8</a>). These findings suggest a dose‐response relationship for actinomycin D and alopecia, and we did not pool these heterogeneous subgroup data (Test for subgroup differences: P value = 0.05; I² = 65.7%). </p> <p>Similarly, mucositis occurred more frequently in the five‐day IV actinomycin D group than the eight‐day MTX‐FA treatment group of <a href="./references#CD007102-bbs2-0002" title="LertkhachonsukA , TangtrakulS , IsranguraN , WilailakS . Actinomycin D versus methotrexate‐folinic acid as the treatment of stage 1, low‐risk gestational trophoblastic neoplasia. Conference abstract from the International Society for the Study of Trophoblastic Disease (ISSTD) conference. 2007. LertkhachonsukAA , IsranguraN , WilailakS , TangtrakulS . Actinomycin d versus methotrexate‐folinic acid as the treatment of stage I, low‐risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer2009;19(5):985‐8. ">Lertkhachonsuk 2009</a>. These data differed from the only other study reporting this outcome and in which the interventions had similar effects on mucositis (<a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a>). Tests for subgroup differences suggest that the effects of these different regimen on the risk of mucositis differ (P value = 0.02; I² = 81%), therefore, we did not pool these data (<a href="./references#CD007102-fig-0014" title="">Analysis 1.9</a>). </p> <p>Dermatological adverse effects (including rash or alopecia) occurred more frequently in the actinomycin D group, in the one study reporting this combined outcome (<a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a>; RR 0.52, 95% CI 0.29 to 0.93; <a href="./references#CD007102-fig-0015" title="">Analysis 1.10</a>), However, these adverse effects were all <a href="./references#CD007102-bbs2-0032" title="Common Terminology Criteria for Adverse Events (CTCAE). National Cancer Institute; available at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html June 14, 2010; Vol. V4.0. ">CTCAE 2010</a> grade one, except for one grade two effect in the methotrexate group. </p> <p>Severe adverse events (SAEs; <a href="./references#CD007102-bbs2-0032" title="Common Terminology Criteria for Adverse Events (CTCAE). National Cancer Institute; available at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html June 14, 2010; Vol. V4.0. ">CTCAE 2010</a> or Gynecologic Oncology Group (GOG) ≥ grade 3) were experienced by participants of two out of the five studies (<a href="./references#CD007102-bbs2-0002" title="LertkhachonsukA , TangtrakulS , IsranguraN , WilailakS . Actinomycin D versus methotrexate‐folinic acid as the treatment of stage 1, low‐risk gestational trophoblastic neoplasia. Conference abstract from the International Society for the Study of Trophoblastic Disease (ISSTD) conference. 2007. LertkhachonsukAA , IsranguraN , WilailakS , TangtrakulS . Actinomycin d versus methotrexate‐folinic acid as the treatment of stage I, low‐risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer2009;19(5):985‐8. ">Lertkhachonsuk 2009</a>; <a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a>). All reported SAEs were grade three except for two women in the actinomycin D group of the <a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a> study who experienced grade four haematological SAEs. The evidence overall suggests that there may be little or no difference between the methotrexate and actinomycin D groups for SAEs; however, the evidence is of a low certainty due to imprecision and inconsistency (five trials, 515 participants; RR 0.35, 95% 0.08 to 1.66; <a href="./references#CD007102-fig-0021" title="">Analysis 1.16</a>; I² = 60%). Five‐day actinomycin D may be associated with a higher risk of SAEs than the eight‐day MTX‐FA regimen (low‐certainty evidence). </p> <p>Six women in the <a href="./references#CD007102-bbs2-0002" title="LertkhachonsukA , TangtrakulS , IsranguraN , WilailakS . Actinomycin D versus methotrexate‐folinic acid as the treatment of stage 1, low‐risk gestational trophoblastic neoplasia. Conference abstract from the International Society for the Study of Trophoblastic Disease (ISSTD) conference. 2007. LertkhachonsukAA , IsranguraN , WilailakS , TangtrakulS . Actinomycin d versus methotrexate‐folinic acid as the treatment of stage I, low‐risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer2009;19(5):985‐8. ">Lertkhachonsuk 2009</a> study and one women in the <a href="./references#CD007102-bbs2-0005" title="ShobeiriMJ , VejdaniR , MelliMS , MadarekEOS , GarebaghiPM , KhoeiSA , et al. Comparison of methotrexate‐folinic acid versus pulsed actinomycin‐d in treatment of stage i, low risk gestational trophoblastic neoplasia: A randomized clinical trial. [Persian]. Iranian Journal of Obstetrics, Gynecology and Infertility2014;17:1‐11. ">Shobeiri 2014</a> had the allocated treatment (MTX‐FA) discontinued due to hepatotoxicity. No other incidents of treatment discontinuation were reported. No deaths occurred in any of the trials. </p> <p>Reproductive data were scarce: only <a href="./references#CD007102-bbs2-0006" title="Rahimi‐MoghaddamP , EftekharZ , YarandiF . Single‐agent therapy for low risk gestational trophoblastic tumor: a comparison between pulse‐methotrexate versus pulse‐actinomycin [abstract]. International Journal of Gynecological Cancer2004;14 Suppl 1:96. YarandiF , EftekharZ , ShojaeiH , KananiS , SharifiA , HanjaniP . Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics2008; Vol. 103, issue 1:33‐7. ">Yarandi 2008</a> reports that "no ovarian failure" occurred. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007102-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007102-sec-0093"></div> <section id="CD007102-sec-0094"> <h3 class="title" id="CD007102-sec-0094">Summary of main results</h3> <p>See <a href="./full#CD007102-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>Seven RCTs were included and six trials evaluating 577 women contributed data. All trials compared methotrexate with actinomycin D. Moderate‐certainty evidence indicates that actinomycin D is probably more likely to be associated with a higher primary cure rate than methotrexate, irrespective of the treatment regimen compared, and less likely to be associated with first‐line treatment failure. </p> <p>Side‐effects were reported to be mild (<a href="./references#CD007102-bbs2-0032" title="Common Terminology Criteria for Adverse Events (CTCAE). National Cancer Institute; available at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html June 14, 2010; Vol. V4.0. ">CTCAE 2010</a> or GOG grade one to two) or minimal in three trials. Low‐certainty evidence suggests that there may be little or no difference in various side‐effects. However, the five‐day actinomycin D regimen may cause more alopecia and mucositis than the eight‐day methotrexate‐folinic acid regimen (MTX‐FA). </p> <p>Overall, it is uncertain whether there is a difference in the risk of severe adverse events (SAEs) between actinomycin D and methotrexate regimens. However, low‐certainty evidence suggests that the five‐day actinomycin D regimen may be more likely to be associated with SAEs than the eight‐day MTX‐FA regimen. </p> </section> <section id="CD007102-sec-0095"> <h3 class="title" id="CD007102-sec-0095">Overall completeness and applicability of evidence</h3> <p>The evidence indicates that actinomycin D is probably better than methotrexate in achieving a primary cure in women with low‐risk GTN. However, three out of seven included trials used a weekly IM dose of methotrexate and it has been argued that this regimen is not as effective as the five‐ or eight‐day regimens (<a href="./references#CD007102-bbs2-0026" title="AghajanianC . Treatment of low‐risk gestational trophoblastic neoplasia. Journal of Clinical Oncology2011;29(7):786‐8. ">Aghajanian 2011</a>). Hence, the ongoing research comparing pulsed actinomycin D with more intensive methotrexate regimens (<a href="./references#CD007102-bbs2-0022" title="ThomasA . Randomised trial of pulsed Actinomycin D versus MTX infusion in low risk gestational trophoblastic neoplasia. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/11/003120 November 19, 2012. ">CTRI/2012/11/003120</a>; <a href="./references#CD007102-bbs2-0023" title="SchinkJC , DiSaia PJ and the Gynecologic Oncology Group. Methotrexate or actinomycin D in treating patients with low‐risk gestational trophoblastic neoplasia. www.clinicaltrials.gov/ct2/show/NCT01535053 14 Feb, 2012. ">GOG 0275</a>; <a href="./references#CD007102-bbs2-0024" title="AbbaslouF . Comparison of pulsed Actinomycin versus 5‐day Methotrexate for the treatment of low‐risk gestational trophoblastic disease in patients. http://www.irct.ir/searchresult.php?id=19567&amp;number=1 Feb 5, 2015. ">IRCT2015012519567N1</a>) is likely to have an important impact on our confidence in this evidence. </p> <p>Although most included studies reported minimal side‐effects and the evidence indicated that there may be little or no difference in side‐effect outcomes, the relative side‐effect profiles of the two drugs is still uncertain. This is largely because interventions and data were frequently heterogeneous. Furthermore, in the two studies with data on SAEs (mainly grade three) (<a href="./references#CD007102-bbs2-0002" title="LertkhachonsukA , TangtrakulS , IsranguraN , WilailakS . Actinomycin D versus methotrexate‐folinic acid as the treatment of stage 1, low‐risk gestational trophoblastic neoplasia. Conference abstract from the International Society for the Study of Trophoblastic Disease (ISSTD) conference. 2007. LertkhachonsukAA , IsranguraN , WilailakS , TangtrakulS . Actinomycin d versus methotrexate‐folinic acid as the treatment of stage I, low‐risk gestational trophoblastic neoplasia: a randomized controlled trial. International Journal of Gynecological Cancer2009;19(5):985‐8. ">Lertkhachonsuk 2009</a>; <a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a>), data were scarce; however, more SAEs occurred in the actinomycin D group. As side‐effects and SAEs play an important role in treatment choice, more evidence on the relative side‐effects is necessary. However, since the efficacy of actinomycin D does not appear to be adversely affected by the lower, pulsed bi‐weekly dosage, which appears to be associated with fewer side‐effects than the five‐day regimen, pulsed actinomycin D may compare favourably in terms of relative side‐effects to the five‐ and eight‐day methotrexate regimens. This was shown in the one small included study (<a href="./references#CD007102-bbs2-0003" title="MousaviA , CheraghiF , YarandiF , GilaniMM , ShojaeiH . Comparison of pulsed actinomycin D versus 5‐day methotrexate for the treatment of low‐risk gestational trophoblastic disease. International Journal of Gynecology and Obstetrics2012;116(1):39‐42. ">Mousavi 2012</a>) in which no significant differences were found between these two groups in terms of side‐effects, and no SAEs occurred. Thus, the ongoing trials are likely to make an important contribution to the body of evidence on SAEs and side‐effects. </p> <p>These results may not be applicable to women with WHO risk scores of five to six and/or those with histologically‐confirmed choriocarcinoma. <a href="./references#CD007102-bbs2-0006" title="Rahimi‐MoghaddamP , EftekharZ , YarandiF . Single‐agent therapy for low risk gestational trophoblastic tumor: a comparison between pulse‐methotrexate versus pulse‐actinomycin [abstract]. International Journal of Gynecological Cancer2004;14 Suppl 1:96. YarandiF , EftekharZ , ShojaeiH , KananiS , SharifiA , HanjaniP . Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics2008; Vol. 103, issue 1:33‐7. ">Yarandi 2008</a> excluded women with histologically‐confirmed choriocarcinoma from their trial, and <a href="./references#CD007102-bbs2-0004" title="OsborneR , FiliaciV , SchinkJ , MannelR , ProvencherD , Alvarez‐SecordA , et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin D as primary management for low‐risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol. 108:S2‐S31. OsborneRJ , FiliaciV , SchinkJC , MannelRS , Alvarez SecordA , KelleyJL , et al. Phase III trial of weekly methotrexate or pulsed actinomycin D for low‐risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Journal of Clinical Oncology2011;29(7):825‐31. ">Osborne 2011</a> found that these higher scoring, low‐risk lesions (previously classified as intermediate risk) were significantly less likely to respond to either drug as single‐agent therapy. In the latter study, the primary response rate for these higher scoring lesions was 9% and 42% for methotrexate and actinomycin D, respectively. This needs further investigation. </p> <p>Women undergoing treatment for low‐risk GTN may wish to bear children in the future. Follow‐up in the included studies was continued for one year after the last treatment cycle and only one mentioned ovarian failure as an potential adverse outcome (<a href="./references#CD007102-bbs2-0006" title="Rahimi‐MoghaddamP , EftekharZ , YarandiF . Single‐agent therapy for low risk gestational trophoblastic tumor: a comparison between pulse‐methotrexate versus pulse‐actinomycin [abstract]. International Journal of Gynecological Cancer2004;14 Suppl 1:96. YarandiF , EftekharZ , ShojaeiH , KananiS , SharifiA , HanjaniP . Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics2008; Vol. 103, issue 1:33‐7. ">Yarandi 2008</a>). Reproductive data should be included in future studies of treatment for low‐risk GTN. </p> <p>As health economics play an increasingly important role in determining treatment guidelines, particularly where several different treatment regimens result in similar cure rates and similar/low rate of side‐effects, the relative cost of treatment and treatment failure needs to be examined. Unfortunately, this was beyond the scope of this review but may be considered for the next update. </p> </section> <section id="CD007102-sec-0096"> <h3 class="title" id="CD007102-sec-0096">Quality of the evidence</h3> <p>The quality of evidence ranges from low to moderate certainty, with evidence most frequently being downgraded due to clinical or statistical inconsistency and/or imprecision. For more details see <a href="./full#CD007102-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD007102-sec-0097"> <h3 class="title" id="CD007102-sec-0097">Potential biases in the review process</h3> <p>To our knowledge there were no potential biases in the review process. We included all the relevant randomised controlled trials (RCTs) identified by the search. Where there were concerns regarding the quality of included trials, we contacted the investigators, and performed sensitivity analyses. We were unable to obtain the full <a href="./references#CD007102-bbs2-0005" title="ShobeiriMJ , VejdaniR , MelliMS , MadarekEOS , GarebaghiPM , KhoeiSA , et al. Comparison of methotrexate‐folinic acid versus pulsed actinomycin‐d in treatment of stage i, low risk gestational trophoblastic neoplasia: A randomized clinical trial. [Persian]. Iranian Journal of Obstetrics, Gynecology and Infertility2014;17:1‐11. ">Shobeiri 2014</a> manuscript for this 2016 update but still hope to do so and, once translated, to include more data from this study in the next update. </p> </section> <section id="CD007102-sec-0098"> <h3 class="title" id="CD007102-sec-0098">Agreements and disagreements with other studies or reviews</h3> <p>The largest contributing subgroup of trials used the weekly methotrexate regimen. This regimen has been criticised as being less effective than the more commonly used methotrexate treatment regimens, namely the five‐ or eight‐day regimens (<a href="./references#CD007102-bbs2-0026" title="AghajanianC . Treatment of low‐risk gestational trophoblastic neoplasia. Journal of Clinical Oncology2011;29(7):786‐8. ">Aghajanian 2011</a>). However, efficacy data on the various methotrexate regimens have come mainly from retrospective (<a href="./references#CD007102-bbs2-0030" title="BagshaweKD , DentJ , NewlandsES , BegentRH , RustinGJ . The role of low‐dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). British Journal of Obstetrics and Gynaecology1989;96(7):795‐802. ">Bagshawe 1989</a>; <a href="./references#CD007102-bbs2-0057" title="McNeishIA , StricklandS , HoldenL , RustinGJ , FoskettM , SecklMJ , et al. Low‐risk persistent gestational trophoblastic disease: outcome after initial treatment with low‐dose methotrexate and folinic acid from 1992 to 2000. Journal of Clinical Oncology2002;20(7):1838‐44. ">McNeish 2002</a>; <a href="./references#CD007102-bbs2-0070" title="SoperJT , Clarke‐PearsonDL , BerchuckA , RodriguezG , HammondCB . 5‐day methotrexate for women with metastatic gestational trophoblastic disease. Gynecological Oncology1994;54(1):76‐9. ">Soper 1994</a>) and case‐control studies (<a href="./references#CD007102-bbs2-0020" title="SmithEB , WeedJCJr , TyreyL , HammondCB . Treatment of nonmetastatic gestational trophoblastic disease: results of methotrexate alone versus methotrexate‐‐folinic acid. American Journal of Obstetrics and Gynecology1982;144(1):88‐92. ">Smith 1982</a>; <a href="./references#CD007102-bbs2-0021" title="WongLC , ChooYC , MaHK . Methotrexate with citrovorum factor rescue in gestational trophoblastic disease. American Journal of Obstetrics and Gynecology1985; Vol. 152, issue 1:59‐62. ">Wong 1985</a>), which may be subject to high levels of bias; furthermore, there have been no RCTs comparing the weekly methotrexate regimen with the five‐ and eight‐day regimens (<a href="#CD007102-fig-0004">Figure 4</a>). Given the wide range of methotrexate and actinomycin D regimens evaluated, and the uncertainty with regard to which regimen is optimal, it would seem appropriate to conduct a network meta‐analysis for the next update of this review, when we should be able to include the data from current ongoing studies. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007102-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram of the original 2009 review*The original 2009 review Included four non‐RCTs (Abrao 2008; Kohorn 1996; Smith 1982; Wong 1985) in the qualitative and three (Abrao 2008 not included) in the quantitative meta‐analysis). These non‐RCTs were excluded in the updated review." data-id="CD007102-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram of the original 2009 review</p> <p>*The original 2009 review Included four non‐RCTs (<a href="./references#CD007102-bbs2-0008" title="AbraoRA , deAndradeJM , TiezziDG , MaranaHR , Candido dos ReisFJ , ClagnanWS . Treatment for low‐risk gestational trophoblastic disease: comparison of single‐agent methotrexate, actinomycin D and combination regimens. Gynecologic Oncology2008; Vol. 108, issue 1:149‐53. ">Abrao 2008</a>; <a href="./references#CD007102-bbs2-0015" title="KohornEI . Decision making for chemotherapy administration in patients with low risk gestational trophoblastic neoplasia. International Journal of Gynecological Cancer1996;6:279‐85. ">Kohorn 1996</a>; <a href="./references#CD007102-bbs2-0020" title="SmithEB , WeedJCJr , TyreyL , HammondCB . Treatment of nonmetastatic gestational trophoblastic disease: results of methotrexate alone versus methotrexate‐‐folinic acid. American Journal of Obstetrics and Gynecology1982;144(1):88‐92. ">Smith 1982</a>; <a href="./references#CD007102-bbs2-0021" title="WongLC , ChooYC , MaHK . Methotrexate with citrovorum factor rescue in gestational trophoblastic disease. American Journal of Obstetrics and Gynecology1985; Vol. 152, issue 1:59‐62. ">Wong 1985</a>) in the qualitative and three (<a href="./references#CD007102-bbs2-0008" title="AbraoRA , deAndradeJM , TiezziDG , MaranaHR , Candido dos ReisFJ , ClagnanWS . Treatment for low‐risk gestational trophoblastic disease: comparison of single‐agent methotrexate, actinomycin D and combination regimens. Gynecologic Oncology2008; Vol. 108, issue 1:149‐53. ">Abrao 2008</a> not included) in the quantitative meta‐analysis). These non‐RCTs were excluded in the updated review. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram of the updated search conducted from January 2010 to February 2012." data-id="CD007102-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram of the updated search conducted from January 2010 to February 2012.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for the updated search conducted from Feb 2012 to January 2016." data-id="CD007102-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram for the updated search conducted from Feb 2012 to January 2016.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Chemotherapy treatment comparisons of included RCTs (solid lines) and ongoing RCTs (dotted lines)" data-id="CD007102-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Chemotherapy treatment comparisons of included RCTs (solid lines) and ongoing RCTs (dotted lines) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007102-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 1 Primary cure (remission)." data-id="CD007102-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 1 Primary cure (remission).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 2 Failure of first line therapy." data-id="CD007102-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 2 Failure of first line therapy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 3 Chemotherapy cycles to primary cure." data-id="CD007102-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 3 Chemotherapy cycles to primary cure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 4 Adverse effects: Nausea." data-id="CD007102-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 4 Adverse effects: Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 5 Adverse effects: Vomiting." data-id="CD007102-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 5 Adverse effects: Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 6 Adverse effects: Diarrhoea." data-id="CD007102-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 6 Adverse effects: Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 7 Adverse effects: Constitutional." data-id="CD007102-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 7 Adverse effects: Constitutional.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 8 Adverse effects: Alopecia." data-id="CD007102-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 8 Adverse effects: Alopecia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 9 Adverse effects: Mucositis/stomatitis." data-id="CD007102-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 9 Adverse effects: Mucositis/stomatitis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 10 Adverse effects: Dermatological." data-id="CD007102-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 10 Adverse effects: Dermatological.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 11 Adverse effects: Neutropenia." data-id="CD007102-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 11 Adverse effects: Neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 12 Adverse effects: Thrombocytopenia." data-id="CD007102-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 12 Adverse effects: Thrombocytopenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 13 Adverse effects: Anaemia." data-id="CD007102-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 13 Adverse effects: Anaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 14 Adverse effects: Hepatotoxicity." data-id="CD007102-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 14 Adverse effects: Hepatotoxicity.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 15 Adverse effects: Haemoptysis." data-id="CD007102-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 15 Adverse effects: Haemoptysis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007102-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/urn:x-wiley:14651858:media:CD007102:CD007102-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_t/tCD007102-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate vs. Actinomycin D, Outcome 16 Severe adverse events (≥G3)." data-id="CD007102-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate vs. Actinomycin D, Outcome 16 Severe adverse events (≥G3).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/media/CDSR/CD007102/image_n/nCD007102-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007102-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Actinomycin D compared with methotrexate (MTX) for low‐risk gestational trophoblastic neoplasia (GTN)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: women withe low‐risk GTN</b> </p> <p><b>Settings: outpatient or hospital</b> </p> <p><b>Intervention: actinomycin D (Act D)</b> </p> <p><b>Comparison: MTX</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Illustrative Assumed risk*</b> </p> <p><b>(Act D)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Illustrative Corresponding risk</b> </p> <p><b>(MTX)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary cure (remission)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>824 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>536 per 1000</p> <p>(470 to 618)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.65</b> (0.57 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>577 women (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Act D is probably more likely to achieve a primary cure than MTX.</p> <p>55% of the data came from trials of weekly IM MTX, which may be less effective than the 5‐ or 8‐day MTX regimens. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure of first‐line therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>154 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>547 per 1000 (279 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.55</b> (1.81 to 6.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>577 women (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Act D as a first‐line treatment is probably less likely to fail than MTX.</p> <p>59% of the data came from trials of weekly IM MTX, which may be less effective than the 5‐ or 8‐day MTX regimens. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe adverse events (≥ grade 3)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>142 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> <p>(11 to 235)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.35</b> (0.08 to 1.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>515 women (5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There may be little or no difference between interventions overall. However, the point estimate and subgroup analyses favoured MTX. SAEs occurred in 3 out of 6 studies, but one study did not contribute to the meta‐analysis due to insufficient data. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>462 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>282 per 1000</p> <p>(134 to 582)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.61</b> (0.29 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>466 women (4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is probably little or no difference between MTX and Act D for nausea.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alopecia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Subtotals only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data on alopecia were not pooled due to substantial subgroup differences. However, in general the evidence suggested that there may be little or no difference between MTX and Act D regimens with regard to alopecia, except for the five‐day Act D regimen, which may be more frequently associated with alopecia than the 8‐day MTX regimen. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> <p>IM = intramuscular; SAE = severe adverse effects</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded for clinical or statistical inconsistency </p> <p><sup>2</sup> Downgraded for imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007102-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">FIGO anatomical staging *</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stage I</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease confined to the uterus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stage II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GTN extends outside of the uterus, but is limited to the genital structures (adnexae, vagina, broad ligament) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stage III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GTN extends to the lungs with or without known genital tract involvement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All other metastatic sites</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>*<a href="./references#CD007102-bbs2-0036" title="FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary and gestational trophoblastic neoplasia. International Journal of Gynaecology and Obstetrics2009;105:3‐4. ">FIGO 2009</a><br/> GTN: </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">FIGO anatomical staging *</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007102-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Modified WHO Prognostic Scoring System as adapted by FIGO for GTN</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scores</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age (years)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antecedent pregnancy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mole</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>abortion</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>term</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interval months from index pregnancy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4–6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7–12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pretreatment serum hCG (IU/L)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10<sup>3</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10<sup>3</sup> to 10<sup>4</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10<sup>4</sup> to 10<sup>5</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 10<sup>5</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Largest tumour size (including uterus)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3cm to 4 cm</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 5 cm</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Site of metastases</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>lung</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>spleen, kidney</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>gastrointestinal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>liver, brain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of metastases</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1to 4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 to 8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Previous failed chemotherapy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>single drug</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 2 drugs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><i>To stage and allot a risk factor score, a patient's diagnosis is allocated to a stage as represented by a Roman numeral I, II, III, and IV. This is then separated by a colon from the sum of all the actual risk factor scores expressed in Arabic numerals, i.e., stage II:4, stage IV:9. This stage and score will be allotted for each patient.(</i><a href="./references#CD007102-bbs2-0036" title="FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary and gestational trophoblastic neoplasia. International Journal of Gynaecology and Obstetrics2009;105:3‐4. ">FIGO 2009</a>). <i>A score ≤ 6 indicates low‐risk; &gt; 6 indicates high‐risk.</i> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>hCG = human chorionic gonadotrophin; IU = Internationa Units</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Modified WHO Prognostic Scoring System as adapted by FIGO for GTN</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007102-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Other first‐line chemotherapy regimens described</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravenous (IV) methotrexate (100, 150, or 300 mg/m²) with folinic acid rescue 24 hours later, repeated weekly </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0029" title="BagshaweKD . Risk and prognostic factors in trophoblastic neoplasia. Cancer1976;38(3):1373‐85. ">Bagshawe 1976</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The original Bagshawe regimen.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bolus (100 mg/m² IV or IM) and 12‐hour continuous methotrexate infusion (200 mg/m²) with folinic acid rescue 24 hours later, repeated fortnightly </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0038" title="GarrettAP , GarnerEO , GoldsteinDP , BerkowitzRS . Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low‐risk metastatic gestational trophoblastic tumors. 15 years of experience. Journal of Reproductive Medicine2002;47(5):355‐62. ">Garrett 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Combined 5‐day methotrexate (day 1 to 5) and 5‐day actinomycin D (day 15 to 19), repeated every 28 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0008" title="AbraoRA , deAndradeJM , TiezziDG , MaranaHR , Candido dos ReisFJ , ClagnanWS . Treatment for low‐risk gestational trophoblastic disease: comparison of single‐agent methotrexate, actinomycin D and combination regimens. Gynecologic Oncology2008; Vol. 108, issue 1:149‐53. ">Abrao 2008</a>; <a href="./references#CD007102-bbs2-0068" title="SmithJP . Chemotherapy in gynecologic cancer. Clinical Obstetrics and Gynecology1975;65:113‐6. ">Smith 1975</a>; <a href="./references#CD007102-bbs2-0064" title="RosePG , PiverMS . Alternating methotrexate and actinomycin D in nonmetastatic gestational trophoblastic disease. Journal of Surgical Oncology1989;41(3):148‐52. ">Rose 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Associated with a high incidence of toxicity.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High‐dose methotrexate (600 mg/m²)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0035" title="ElitL , CovensA , OsborneR , GerulathA , MurphyJ , RosenB , et al. High‐dose methotrexate for gestational trophoblastic disease. Gyncologic Oncology1994;54(3):282‐7. ">Elit 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not effect a higher cure than other methotrexate regimens.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Etoposide (oral and parenteral)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0045" title="HitchinsRN , HoldenL , NewlandsES , BegentRH , RustinGJ , BagshaweKD . Single agent etoposide in gestational trophoblastic tumours. Experience at Charing Cross Hospital 1978‐1987. European Journal of Cancer and Clinical Oncology1988;24(6):1041‐6. ">Hitchins 1988</a>; <a href="./references#CD007102-bbs2-0076" title="WongLC , ChooYC , MaHK . Oral etoposide in gestational trophoblastic disease. Cancer Treatment Reports1984;68(5):775‐7. ">Wong 1984</a>; <a href="./references#CD007102-bbs2-0077" title="WongLC , ChooYC , MaHK . Primary oral etoposide therapy in gestational trophoblastic disease. An update. Cancer1986;58(1):14‐7. ">Wong 1986</a>; <a href="./references#CD007102-bbs2-0009" title="BaptistaAM , BelfortP . Comparison of methotrexate, actinomycin D, and etoposide for treating low‐risk gestational trophoblastic neoplasia. International Journal of Gynaecology and Obstetrics2012;119:35‐8. ">Baptista 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported to be highly effective but not widely used for low‐risk GTN due to the high risk of side‐effects, particularly alopecia. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluorouracil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0072" title="SungHC , WuPC , WangYB . Re‐evaluation of 5‐fluorouracil as a single agent for gestational malignant trophoblastic neoplasms. Advances in Experimental Medicine and Biology1984;176:355‐67. ">Sung 1984</a>; <a href="./references#CD007102-bbs2-0069" title="SongHZ , YangXY , XiangY . Forty‐five year's experience of the treatment of choriocarcinoma and invasive mole. International Journal of Gynaecology and Obstetrics1998;60 Suppl 1:S77‐83. ">Song 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Used in China for several decades, mainly because of its low cost, but is not favoured elsewhere. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intra‐lesional methotrexate infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0071" title="SuWH , WangPH , ChangSP . Successful treatment of a persistent mole with myometrial invasion by direct injection of methotrexate. European Journal of Gynaecological Oncology2001;22(4):283‐6. ">Su 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not favoured in Europe or North America.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese preparations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007102-bbs2-0074" title="WangY , JiuL , GuanY , QiuD . Chemotherapy using 5‐fluorouracil and nitrocaphanum in malignant trophoblastic tumor. Gynecologic Oncology1998;71(3):416‐9. ">Wang 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not favoured in Europe or North America.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>GTN = gestational trophoblastic neoplasia</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Other first‐line chemotherapy regimens described</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/full#CD007102-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007102-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Methotrexate vs. Actinomycin D</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary cure (remission) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.57, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.48, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Five‐day IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.57, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Eight‐day IM MTX‐FA vs. 5‐day IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.40, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Eight‐day IM MTX‐FA vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.50, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Failure of first line therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.55 [1.81, 6.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.54 [1.12, 11.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Five‐day IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.2 [1.17, 8.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Eight‐day IM MTX‐FA vs. 5‐day IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.58 [1.16, 297.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Eight‐day IM MTX‐FA vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.25 [1.19, 8.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Chemotherapy cycles to primary cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [0.93, 5.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Five‐day IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐2.87, ‐1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Eight‐day IM MTX‐FA vs. 5‐day IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [‐0.27, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects: Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.29, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.11, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Five‐day IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.72, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects: Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.32, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.24, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Five‐day IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.50, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.85, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.57, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Five‐day IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.58, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: Constitutional <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.84, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.79, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Five‐day IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.78, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: Alopecia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.27, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Five‐day IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.41, 4.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Eight‐day IM MTX‐FA vs. 5‐day IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: Mucositis/stomatitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.39, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Eight‐day IM MTX‐FA vs. 5‐day IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.03, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: Dermatological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.48, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.38, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Five‐day IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.43, 9.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Eight‐day IM MTX‐FA vs. 5‐day IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [0.27, 21.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.16, 3.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.12, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Five‐day IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.5 [0.74, 8.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Eight‐day IM MTX‐FA vs. 5‐day IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.01, 6.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: Anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: Hepatotoxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.39, 16.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.56, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Eight‐day IM MTX‐FA vs. 5‐day IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.68 [0.63, 179.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: Haemoptysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.30, 3.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.13, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Five‐day IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.30, 13.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Severe adverse events (≥G3) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.08, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Weekly IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.35, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Five‐day IM MTX vs. pulsed IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Eight‐day IM MTX‐FA vs. 5‐day IV Act D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.02, 0.88]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Methotrexate vs. Actinomycin D</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007102.pub4/references#CD007102-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007102.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007102-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007102-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD007102-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD007102-note-0007">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD007102-note-0002">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD007102-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD007102-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007102-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007102\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007102\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007102\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007102\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007102\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007102.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007102.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007102.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007102.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007102.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718454572"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007102.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718454575"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007102.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd0ba4c11f401',t:'MTc0MDcxODQ1NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 